Existence	O
of	O
retinoic	B-protein
acid-receptor	I-protein
-independent	O
retinoid	B-protein
X-receptor	I-protein
-dependent	O
pathway	O
in	O
myeloid	B-cell_type
cell	I-cell_type
function	O
.	O

We	O
previously	O
reported	O
that	O
ER-27191	O
(	O
4-	O
[	O
4	O
,	O
5	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10-hexahydro-7	O
,	O
7	O
,	O
10	O
,	O
10-tetramethyl-1-	O
(	O
3-pyridylmethyl	O
)	O
anthra	O
[	O
1	O
,	O
2-b	O
]	O
pyrrol-3-yl	O
]	O
benzoic	O
acid	O
)	O
is	O
a	O
potent	O
antagonist	O
of	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
,	O
and	O
ER-35795	O
(	O
(	O
2E	O
,	O
4E	O
,	O
6E	O
)	O
-7-	O
[	O
1-	O
(	O
1-methylethyl	O
)	O
-8-chloro-1	O
,	O
2	O
,	O
3	O
,	O
4-tetrahydroquinolin-6-yl	O
]	O
-6-fluoro-3-methyl-2	O
,	O
4	O
,	O
6-nonatrienoic	O
acid	O
)	O
is	O
a	O
novel	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	O
RXR	B-protein
)	O
-specific	O
agonist	O
.	O

By	O
using	O
these	O
compounds	O
,	O
we	O
investigated	O
whether	O
distinct	O
RAR	B-protein
-dependent	O
and	O
RXR	B-protein
-dependent	O
pathways	O
operate	O
to	O
mediate	O
the	O
diverse	O
activities	O
of	O
retinoids	O
,	O
particularly	O
,	O
the	O
effects	O
of	O
the	O
RXR	B-protein
pathway	O
on	O
cellular	O
function	O
.	O

ER-27191	O
completely	O
antagonized	O
HL60	B-cell_line
cell	I-cell_line
differentiation	O
induced	O
by	O
all-trans-retinoic	O
acid	O
(	O
atRA	O
)	O
.	O

However	O
,	O
the	O
differentiation	O
induced	O
by	O
the	O
ER-35795	O
was	O
not	O
antagonized	O
at	O
all	O
by	O
the	O
RAR	B-protein
antagonist	O
,	O
but	O
was	O
inhibited	O
by	O
an	O
RXR	B-protein
homodimer	I-protein
antagonist	O
(	O
LGD100754	O
,	O
(	O
2E	O
,	O
4E	O
,	O
6Z	O
)	O
-7-	O
(	O
3-n-propoxy-5	O
,	O
6	O
,	O
7	O
,	O
8-tetrahydro-5	O
,	O
5	O
,	O
8	O
,	O
8-tetramethylnaphthalen-2-yl	O
)	O
-3-methylocta-2	O
,	O
4	O
,	O
6-trienoic	O
acid	O
)	O
.	O

Its	O
agonistic	O
action	O
on	O
RXR/RAR	B-protein
heterodimer	I-protein
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
neutralized	O
by	O
the	O
RAR	B-protein
antagonist	O
.	O

During	O
HL60	B-cell_line
cell	I-cell_line
differentiation	O
,	O
atRA	O
induced	O
RARbeta	B-RNA
mRNA	I-RNA
,	O
while	O
the	O
RXR	B-protein
had	O
no	O
effect	O
.	O

Interestingly	O
,	O
a	O
functional	O
RXR	B-protein
-pathway	O
was	O
also	O
seen	O
in	O
lipopolysaccharide-induced	O
inhibition	O
of	O
mouse	B-cell_type
splenocyte	I-cell_type
proliferation	O
.	O

These	O
results	O
strongly	O
suggest	O
the	O
existence	O
of	O
a	O
pharmacological	O
RXR	B-protein
-dependent	O
pathway	O
that	O
is	O
activated	O
by	O
a	O
ligand	O
that	O
can	O
bind	O
to	O
RXR	B-protein
.	O

Jpn	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

85	NULL
,	NULL
60-69	NULL
(	NULL
2001	NULL
)	NULL
Existence	NULL
of	NULL
Retinoic	NULL
Acid-Receptor-Independent	NULL
Retinoid	NULL
X-Receptor-	NULL
Dependent	NULL
Pathway	NULL
in	NULL
Myeloid	NULL
Cell	NULL
Function	NULL
Takayuki	NULL
Hida*	NULL
,	NULL
Kenji	NULL
Tai	NULL
,	NULL
Naoki	NULL
Tokuhara	NULL
,	NULL
Akira	NULL
Ishibashi	NULL
,	NULL
Kouichi	NULL
Kikuchi	NULL
,	NULL
Shigeki	NULL
Hibi	NULL
,	NULL
Hiroyuki	NULL
Yoshimura	NULL
,	NULL
Mitsuo	NULL
Nagai	NULL
,	NULL
Toshihiko	NULL
Yamauchi	NULL
and	NULL
Seiichi	NULL
Kobayashi	NULL
Tsukuba	NULL
Research	NULL
Laboratories	NULL
for	NULL
Drug	NULL
Discovery	NULL
,	NULL
Eisai	NULL
Co.	NULL
,	NULL
Ltd.	NULL
,	NULL
5-1-3	NULL
Tokodai	NULL
,	NULL
Tsukuba-shi	NULL
,	NULL
Ibaraki	NULL
300-2635	NULL
,	NULL
Japan	NULL
Received	NULL
March	NULL
28	NULL
,	NULL
2000	NULL
-	NULL
Accepted	NULL
October	NULL
19	NULL
,	NULL
2000	NULL
ABSTRACT-We	NULL
previously	NULL
reported	NULL
that	NULL
ER-27191	NULL
(	NULL
4-	NULL
[	NULL
4,5,7,8,9,10-hexahydro-7,7,10,10-tetramethyl-1-	NULL
(	NULL
3-pyridyImethyl	NULL
)	NULL
anthra	NULL
[	NULL
1,2-b	NULL
]	NULL
pyrrol-3-yl	NULL
]	NULL
benzoic	NULL
acid	NULL
)	NULL
is	NULL
a	NULL
potent	NULL
antagonist	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
(	NULL
RAR	NULL
)	NULL
,	NULL
and	NULL
ER-35795	NULL
(	NULL
(	NULL
25,4£,6E	NULL
)	NULL
-7-	NULL
[	NULL
1-	NULL
(	NULL
1-methylethyl1	NULL
)	NULL
-8-chloro-1,2,3,4-tetrahydroquinolin-6-yl	NULL
]	NULL
-6-fluoro-3-methyl-2,4,6-nonatrienoic	NULL
acid	NULL
)	NULL
is	NULL
a	NULL
novel	NULL
retinoid	NULL
X	NULL
receptor	NULL
(	NULL
RXR	NULL
)	NULL
-specific	NULL
agonist	NULL
.	NULL

By	NULL
using	NULL
these	NULL
com-pounds	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
distinct	NULL
RAR-dependent	NULL
and	NULL
RXR-dependent	NULL
pathways	NULL
operate	NULL
to	NULL
mediate	NULL
the	NULL
diverse	NULL
activities	NULL
of	NULL
retinoids	NULL
,	NULL
particularly	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
RXR	NULL
pathway	NULL
on	NULL
cellular	NULL
function	NULL
.	NULL

ER-27191	NULL
completely	NULL
antagonized	NULL
HL60	NULL
cell	NULL
differentiation	NULL
induced	NULL
by	NULL
al/-trans-retinoic	NULL
acid	NULL
(	NULL
atRA	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
differentiation	NULL
induced	NULL
by	NULL
the	NULL
ER-35795	NULL
was	NULL
not	NULL
antagonized	NULL
at	NULL
all	NULL
by	NULL
the	NULL
RAR	NULL
antagonist	NULL
,	NULL
but	NULL
was	NULL
inhibited	NULL
by	NULL
an	NULL
RXR	NULL
homodimer	NULL
antagonist	NULL
(	NULL
LGD100754	NULL
,	NULL
(	NULL
25,4£,6Z	NULL
)	NULL
-7-	NULL
(	NULL
3-n-propoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyInaphthalen-2-yl	NULL
)	NULL
-3-methylocta-2,4,6-trienoic	NULL
acid	NULL
)	NULL
.	NULL

Its	NULL
agonistic	NULL
action	NULL
on	NULL
RXR/RAR	NULL
heterodimer	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
was	NULL
neutralized	NULL
by	NULL
the	NULL
RAR	NULL
antagonist	NULL
.	NULL

During	NULL
HL60	NULL
cell	NULL
differentiation	NULL
,	NULL
atRA	NULL
induced	NULL
mRNA	NULL
,	NULL
while	NULL
the	NULL
RXR	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
functional	NULL
RXR-pathway	NULL
was	NULL
also	NULL
seen	NULL
in	NULL
lipopolysaccharide-induced	NULL
inhibition	NULL
of	NULL
mouse	NULL
splenocyte	NULL
proliferation	NULL
.	NULL

These	NULL
results	NULL
strongly	NULL
suggest	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
pharmacological	NULL
RXR-dependent	NULL
pathway	NULL
that	NULL
is	NULL
activated	NULL
by	NULL
a	NULL
ligand	NULL
that	NULL
can	NULL
bind	NULL
to	NULL
RXR	NULL
.	NULL

Keywords	NULL
:	NULL
Retinoic	NULL
acid	NULL
receptor	NULL
,	NULL
Retinoid	NULL
X	NULL
receptor	NULL
,	NULL
ER-27191	NULL
,	NULL
ER-35795	NULL
,	NULL
HL60	NULL
differentiation	NULL
Research	NULL
to	NULL
elucidate	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
transactivation	NULL
via	NULL
RAR	NULL
and	NULL
RXR	NULL
,	NULL
members	NULL
of	NULL
the	NULL
nuclear	NULL
receptor	NULL
family	NULL
,	NULL
is	NULL
advancing	NULL
rapidly	NULL
.	NULL

atRA	NULL
is	NULL
known	NULL
as	NULL
a	NULL
multifunctional	NULL
physiological	NULL
regulator	NULL
of	NULL
cell	NULL
proliferation	NULL
and	NULL
differentiation	NULL
(	NULL
reviewed	NULL
in	NULL
refs	NULL
.	NULL

1-3	NULL
)	NULL
.	NULL

Because	NULL
atRA	NULL
binds	NULL
only	NULL
to	NULL
RARs	NULL
,	NULL
the	NULL
biological	NULL
activities	NULL
induced	NULL
by	NULL
atRA	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
mediated	NULL
via	NULL
RARs	NULL
,	NULL
On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
ICRA	NULL
,	NULL
an	NULL
isomer	NULL
of	NULL
atRA	NULL
,	NULL
was	NULL
identified	NULL
as	NULL
a	NULL
ligand	NULL
of	NULL
RXR	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

Since	NULL
IcRA	NULL
can	NULL
bind	NULL
not	NULL
only	NULL
to	NULL
RXR	NULL
,	NULL
but	NULL
also	NULL
to	NULL
RAR	NULL
(	NULL
4-6	NULL
)	NULL
,	NULL
the	NULL
mechanisms	NULL
of	NULL
its	NULL
actions	NULL
appear	NULL
to	NULL
be	NULL
complicated	NULL
.	NULL

Many	NULL
nuclear	NULL
receptors	NULL
activate	NULL
transcription	NULL
by	NULL
forming	NULL
*Corresponding	NULL
author	NULL
.	NULL

-	NULL
FAX	NULL
:	NULL
+81-298-47-2037	NULL
E-mail	NULL
:	NULL
t-hida	NULL
@	NULL
hhc.eisai.co.jp	NULL
heterodimers	NULL
with	NULL
RXR	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
specific	NULL
ligand	NULL
.	NULL

During	NULL
heterodimer	NULL
activation	NULL
,	NULL
RXR	NULL
was	NULL
thought	NULL
to	NULL
be	NULL
a	NULL
silent	NULL
promiscuous	NULL
partner	NULL
.	NULL

Recent	NULL
findings	NULL
showed	NULL
that	NULL
RXR	NULL
ligands	NULL
can	NULL
enhance	NULL
heterodimer	NULL
formation	NULL
with	NULL
a	NULL
counter	NULL
receptor	NULL
,	NULL
such	NULL
as	NULL
RAR	NULL
or	NULL
PPAR	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
demonstrated	NULL
that	NULL
the	NULL
function	NULL
of	NULL
the	NULL
heterodimer	NULL
was	NULL
modified	NULL
by	NULL
RXR	NULL
ligands	NULL
(	NULL
9	NULL
)	NULL
and	NULL
that	NULL
IcRA	NULL
can	NULL
activate	NULL
heterodimer	NULL
formation	NULL
of	NULL
some	NULL
orphan	NULL
receptors	NULL
with	NULL
RXR	NULL
(	NULL
9-11	NULL
)	NULL
.	NULL

In	NULL
any	NULL
case	NULL
,	NULL
the	NULL
cellular	NULL
pathway	NULL
induced	NULL
by	NULL
RXR	NULL
ligands	NULL
as	NULL
well	NULL
as	NULL
the	NULL
participation	NULL
of	NULL
IcRA	NULL
in	NULL
physiological	NULL
nuclear	NULL
receptor	NULL
signaling	NULL
is	NULL
still	NULL
unclear	NULL
.	NULL

To	NULL
better	NULL
understand	NULL
the	NULL
cellular	NULL
mechanisms	NULL
that	NULL
depend	NULL
on	NULL
RXR	NULL
,	NULL
many	NULL
RXR-selective	NULL
compounds	NULL
were	NULL
syn-thesized	NULL
.	NULL

RXR	NULL
agonists	NULL
are	NULL
reported	NULL
to	NULL
affect	NULL
myeloid	NULL
cell	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
(	NULL
in	NULL
alphabetical	NULL
order	NULL
)	NULL
:	NULL
CRBP	NULL
I	NULL
,	NULL
cellular	NULL
retinol-binding	NULL
protein	NULL
I	NULL
;	NULL
CRBP	NULL
II	NULL
,	NULL
cellular	NULL
retinol-binding	NULL
protein	NULL
II	NULL
;	NULL
DMEM	NULL
,	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
;	NULL
DMSO	NULL
,	NULL
dimethyl	NULL
sulfoxide	NULL
;	NULL
ER-27191	NULL
,	NULL
4-	NULL
[	NULL
4,5,7,8,9,10-hexahydro-7,7,10,10-tetramethyl-1-	NULL
(	NULL
3-pyridyl-methyl	NULL
)	NULL
anthra	NULL
[	NULL
1,2-b	NULL
]	NULL
pyrrol-3-yl	NULL
]	NULL
benzoic	NULL
acid	NULL
;	NULL
ER-35795	NULL
,	NULL
(	NULL
25,4£,6E	NULL
)	NULL
-7-	NULL
[	NULL
1-	NULL
(	NULL
1-methylethy1	NULL
)	NULL
-8-chloro-1,2,3,4-tetrahydroquinolin-6-yl	NULL
]	NULL
-6-fluoro-3-methy1-2,4,6-nonatrienoic	NULL
acid	NULL
;	NULL
FBS	NULL
,	NULL
fetal	NULL
bovine	NULL
serum	NULL
;	NULL
LGD100754	NULL
,	NULL
(	NULL
25,45,62	NULL
)	NULL
-7-	NULL
(	NULL
3-n-propoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethy	NULL
Inaphtha-len-2-yl	NULL
)	NULL
-3-methylocta-2,4,6-trienoic	NULL
acid	NULL
;	NULL
LPS	NULL
,	NULL
lipopolysaccharide	NULL
;	NULL
PLAP	NULL
,	NULL
placenta-derived	NULL
secretion-type	NULL
alkaline	NULL
phosphatase	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
PPAR	NULL
,	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
;	NULL
IcRA	NULL
,	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
;	NULL
atRA	NULL
,	NULL
all-trans-retinoic	NULL
acid	NULL
;	NULL
RAR	NULL
,	NULL
retinoic	NULL
acid	NULL
receptor	NULL
;	NULL
RARE	NULL
,	NULL
retinoic	NULL
acid-responsive	NULL
element	NULL
;	NULL
RT-PCR	NULL
,	NULL
reverse	NULL
transcription-polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
RXR	NULL
,	NULL
retinoid	NULL
X	NULL
receptor	NULL
.	NULL

RXR	NULL
Pathway	NULL
in	NULL
Cellular	NULL
Function	NULL
61	NULL
differentiation	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
,	NULL
induction	NULL
of	NULL
apoptosis	NULL
(	NULL
14	NULL
)	NULL
,	NULL
inhibition	NULL
of	NULL
cytokine	NULL
production	NULL
(	NULL
15	NULL
)	NULL
and	NULL
lowering	NULL
blood	NULL
glucose	NULL
level	NULL
in	NULL
diabetes	NULL
models	NULL
(	NULL
7	NULL
,	NULL
16	NULL
)	NULL
.	NULL

It	NULL
was	NULL
often	NULL
observed	NULL
that	NULL
RXR	NULL
ligands	NULL
show	NULL
different	NULL
effects	NULL
from	NULL
the	NULL
ligand	NULL
of	NULL
the	NULL
counter	NULL
receptor	NULL
;	NULL
these	NULL
ligands	NULL
are	NULL
referred	NULL
to	NULL
as	NULL
rexi-noids	NULL
,	NULL
which	NULL
are	NULL
particularly	NULL
distinguished	NULL
from	NULL
retinoids	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
transgenic	NULL
mouse	NULL
experiments	NULL
showed	NULL
a	NULL
role	NULL
of	NULL
an	NULL
RXR-selective	NULL
signal	NULL
in	NULL
the	NULL
development	NULL
of	NULL
the	NULL
spinal	NULL
cord	NULL
(	NULL
17	NULL
)	NULL
and	NULL
organ	NULL
formation	NULL
in	NULL
embryos	NULL
(	NULL
18-20	NULL
)	NULL
.	NULL

Re-cently	NULL
,	NULL
evidence	NULL
suggesting	NULL
the	NULL
existence	NULL
of	NULL
an	NULL
RXR-spe-cific	NULL
,	NULL
non-silent	NULL
,	NULL
pathway	NULL
is	NULL
increasing	NULL
.	NULL

A	NULL
clarification	NULL
concerning	NULL
IcRA	NULL
and/or	NULL
synthetic	NULL
ligand	NULL
in	NULL
the	NULL
RXR	NULL
pathway	NULL
will	NULL
therefore	NULL
be	NULL
helpful	NULL
to	NULL
understand	NULL
the	NULL
physiological	NULL
functions	NULL
of	NULL
RXR	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
clarified	NULL
the	NULL
distinct	NULL
RAR-dependent	NULL
and	NULL
RXR-dependent	NULL
pathways	NULL
in	NULL
the	NULL
functional	NULL
differentiation	NULL
of	NULL
the	NULL
HL60	NULL
cell	NULL
and	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
normal	NULL
B	NULL
cell	NULL
proliferation	NULL
by	NULL
using	NULL
natural	NULL
and	NULL
synthetic	NULL
RXR	NULL
agonists	NULL
in	NULL
combination	NULL
with	NULL
an	NULL
RXR	NULL
homodimer	NULL
antagonist	NULL
and	NULL
an	NULL
RAR	NULL
antagonist	NULL
.	NULL

We	NULL
describe	NULL
here	NULL
the	NULL
existence	NULL
of	NULL
an	NULL
RXR-dependent	NULL
pharmacological	NULL
pathway	NULL
which	NULL
is	NULL
activated	NULL
by	NULL
a	NULL
ligand	NULL
that	NULL
can	NULL
bind	NULL
to	NULL
RXR	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Chemicals	NULL
Unlabeled	NULL
atRA	NULL
was	NULL
purchased	NULL
from	NULL
Sigma	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

PHJatRA	NULL
and	NULL
[	NULL
PH	NULL
]	NULL
I9cRA	NULL
were	NULL
purchased	NULL
from	NULL
DuPont/NEN	NULL
(	NULL
Boston	NULL
,	NULL
MA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

The	NULL
method	NULL
for	NULL
synthesis	NULL
of	NULL
ER-27191	NULL
and	NULL
ER-35795	NULL
was	NULL
reported	NULL
previously	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Retinoid	NULL
compounds	NULL
used	NULL
here	NULL
were	NULL
synthesized	NULL
in	NULL
our	NULL
laboratories	NULL
.	NULL

These	NULL
retinoids	NULL
were	NULL
dissolved	NULL
in	NULL
DMSO	NULL
to	NULL
prepare	NULL
10	NULL
mM	NULL
stock	NULL
solutions	NULL
,	NULL
which	NULL
were	NULL
diluted	NULL
in	NULL
buffer	NULL
or	NULL
culture	NULL
medium	NULL
to	NULL
give	NULL
a	NULL
final	NULL
DMSO	NULL
concentration	NULL
not	NULL
exceeding	NULL
0.1	NULL
%	NULL
.	NULL

Binding	NULL
assay	NULL
To	NULL
estimate	NULL
binding	NULL
affinity	NULL
to	NULL
receptors	NULL
,	NULL
RAR-expressing	NULL
stable	NULL
transformants	NULL
(	NULL
derived	NULL
from	NULL
baby	NULL
hamster	NULL
kidney	NULL
cell	NULL
)	NULL
were	NULL
established	NULL
,	NULL
and	NULL
the	NULL
method	NULL
of	NULL
nuclear	NULL
extract	NULL
preparation	NULL
and	NULL
binding	NULL
assay	NULL
were	NULL
described	NULL
previously	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
a	NULL
180-wl	NULL
aliquot	NULL
of	NULL
nuclear	NULL
extract	NULL
was	NULL
incubated	NULL
with	NULL
10	NULL
wl	NULL
of	NULL
10	NULL
nM	NULL
[	NULL
PHJatRA	NULL
or	NULL
15	NULL
nM	NULL
[	NULL
PH	NULL
]	NULL
I9cRA	NULL
and	NULL
10	NULL
l	NULL
of	NULL
various	NULL
concentrations	NULL
of	NULL
unlabeled	NULL
compounds	NULL
in	NULL
a	NULL
96-well	NULL
polypropylene	NULL
plate	NULL
.	NULL

The	NULL
plate	NULL
was	NULL
incubated	NULL
for	NULL
16	NULL
h	NULL
at	NULL
4°C	NULL
,	NULL
then	NULL
50	NULL
wl/well	NULL
of	NULL
a	NULL
charcoal	NULL
/dextran	NULL
suspension	NULL
(	NULL
3	NULL
%	NULL
Norit	NULL
A	NULL
/	NULL
0.3	NULL
%	NULL
dextran	NULL
in	NULL
10	NULL
mM	NULL
Tris-HCI	NULL
,	NULL
pH7.4	NULL
,	NULL
0.02	NULL
%	NULL
sodium	NULL
azide	NULL
)	NULL
was	NULL
added	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
plate	NULL
was	NULL
centrifuged	NULL
and	NULL
the	NULL
supernatants	NULL
were	NULL
subjected	NULL
to	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

Binding	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
1000-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
ligand	NULL
was	NULL
defined	NULL
as	NULL
nonspecific	NULL
binding	NULL
.	NULL

Specific	NULL
binding	NULL
was	NULL
defined	NULL
as	NULL
the	NULL
total	NULL
binding	NULL
minus	NULL
the	NULL
nonspecific	NULL
binding	NULL
,	NULL
and	NULL
IC	NULL
;	NULL
,	NULL
values	NULL
were	NULL
obtained	NULL
from	NULL
logarithmic	NULL
plots	NULL
.	NULL

The	NULL
selectivities	NULL
of	NULL
compounds	NULL
for	NULL
each	NULL
receptor	NULL
were	NULL
indicated	NULL
as	NULL
relative	NULL
ICs	NULL
,	NULL
,	NULL
obtained	NULL
by	NULL
dividing	NULL
the	NULL
IC	NULL
;	NULL
,	NULL
value	NULL
for	NULL
each	NULL
receptor	NULL
of	NULL
the	NULL
compound	NULL
by	NULL
that	NULL
of	NULL
the	NULL
natural	NULL
ligand	NULL
(	NULL
atRA	NULL
or	NULL
IcRA	NULL
)	NULL
.	NULL

Transactivation	NULL
assay	NULL
To	NULL
evaluate	NULL
transactivation	NULL
activity	NULL
,	NULL
receptor	NULL
expression	NULL
and	NULL
reporter	NULL
plasmids	NULL
were	NULL
transiently	NULL
co-transfected	NULL
in	NULL
COS-1	NULL
cells	NULL
.	NULL

For	NULL
antagonist	NULL
evaluation	NULL
,	NULL
only	NULL
reporter	NULL
plasmid	NULL
was	NULL
transfected	NULL
into	NULL
the	NULL
RAR-expressing	NULL
stable	NULL
transformant	NULL
cells	NULL
.	NULL

The	NULL
cells	NULL
at	NULL
80	NULL
%	NULL
confluence	NULL
in	NULL
a	NULL
60-mm	NULL
dish	NULL
were	NULL
incubated	NULL
with	NULL
6	NULL
wg	NULL
of	NULL
receptor	NULL
expression	NULL
vector	NULL
,	NULL
6	NULL
ug	NULL
of	NULL
reporter	NULL
plasmid	NULL
,	NULL
and	NULL
40	NULL
wl	NULL
of	NULL
Lipofectamine	NULL
``	NULL
(	NULL
Gibco-BRL	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
,	NULL
USA	NULL
)	NULL
per	NULL
dish	NULL
in	NULL
OPTTI-MEM	NULL
(	NULL
Gibco-BRL	NULL
)	NULL
.	NULL

After	NULL
4	NULL
h	NULL
of	NULL
incubation	NULL
,	NULL
the	NULL
medium	NULL
was	NULL
replaced	NULL
with	NULL
DMEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FBS	NULL
and	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
20	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
suspended	NULL
in	NULL
DMEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FBS	NULL
and	NULL
seeded	NULL
at	NULL
3	NULL
x	NULL
10°	NULL
per	NULL
well	NULL
in	NULL
96-well	NULL
plates	NULL
.	NULL

After	NULL
6	NULL
h	NULL
of	NULL
incubation	NULL
,	NULL
compounds	NULL
at	NULL
various	NULL
concentrations	NULL
were	NULL
added	NULL
to	NULL
duplicate	NULL
wells	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
a	NULL
further	NULL
48	NULL
h	NULL
,	NULL
and	NULL
then	NULL
PLAP	NULL
activity	NULL
of	NULL
the	NULL
cell	NULL
supernatants	NULL
was	NULL
assayed	NULL
for	NULL
transcriptional	NULL
activity	NULL
.	NULL

To	NULL
inactivate	NULL
nonspecific	NULL
activity	NULL
,	NULL
the	NULL
samples	NULL
were	NULL
preheated	NULL
at	NULL
65°C	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Aliquots	NULL
of	NULL
15	NULL
ul	NULL
were	NULL
mixed	NULL
with	NULL
60	NULL
wl	NULL
of	NULL
assay	NULL
buffer	NULL
(	NULL
0.28	NULL
M	NULL
Na	NULL
;	NULL
COs	NULL
;	NULL
,	NULL
pH	NULL
10.0	NULL
,	NULL
with	NULL
8	NULL
mM	NULL
MgSQO,4	NULL
)	NULL
and	NULL
reacted	NULL
with	NULL
75	NULL
ul	NULL
of	NULL
Lumistain'®	NULL
``	NULL
(	NULL
Sumitomo	NULL
,	NULL
Osaka	NULL
)	NULL
.	NULL

After	NULL
the	NULL
reaction	NULL
mixture	NULL
had	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
and	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
chemiluminescence	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
micro	NULL
plate	NULL
luminometer	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
selectivities	NULL
for	NULL
each	NULL
receptor	NULL
were	NULL
also	NULL
presented	NULL
as	NULL
relative	NULL
ED	NULL
;	NULL
,	NULL
.	NULL

Because	NULL
in	NULL
our	NULL
investigation	NULL
,	NULL
it	NULL
was	NULL
found	NULL
that	NULL
the	NULL
response	NULL
to	NULL
some	NULL
RAR-selective	NULL
compound	NULL
tended	NULL
to	NULL
reach	NULL
a	NULL
plateau	NULL
near	NULL
50	NULL
%	NULL
of	NULL
that	NULL
of	NULL
atRA	NULL
.	NULL

Therefore	NULL
,	NULL
ED	NULL
;	NULL
,	NULL
values	NULL
were	NULL
used	NULL
to	NULL
represent	NULL
the	NULL
transcriptional	NULL
activity	NULL
for	NULL
the	NULL
evaluation	NULL
.	NULL

HL60	NULL
culture	NULL
and	NULL
differentiation	NULL
measurements	NULL
HL60	NULL
culture	NULL
and	NULL
measurement	NULL
of	NULL
CD11b	NULL
expression	NULL
(	NULL
as	NULL
the	NULL
marker	NULL
of	NULL
differentiation	NULL
)	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
HL60	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10°/ml	NULL
)	NULL
were	NULL
exposed	NULL
to	NULL
compounds	NULL
for	NULL
5	NULL
days	NULL
;	NULL
and	NULL
for	NULL
surface	NULL
antigen	NULL
analysis	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
exposed	NULL
to	NULL
FITC-anti	NULL
CD11b	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Immunotech	NULL
,	NULL
Marseille	NULL
,	NULL
France	NULL
)	NULL
at	NULL
4°C	NULL
for	NULL
1	NULL
h	NULL
,	NULL
and	NULL
fixed	NULL
with	NULL
0.2	NULL
%	NULL
paraform-aldehyde	NULL
.	NULL

The	NULL
proportion	NULL
of	NULL
CD11b-positive	NULL
cells	NULL
in	NULL
viable	NULL
cells	NULL
was	NULL
determined	NULL
with	NULL
a	NULL
FACScan	NULL
``	NULL
(	NULL
Becton	NULL
Dickin-son	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

In	NULL
some	NULL
cases	NULL
,	NULL
we	NULL
also	NULL
measured	NULL
the	NULL
magnitude	NULL
of	NULL
superoxide	NULL
anion	NULL
production	NULL
from	NULL
HL60	NULL
cells	NULL
as	NULL
a	NULL
functional	NULL
differentiation	NULL
marker	NULL
.	NULL

For	NULL
measurement	NULL
of	NULL
superoxide	NULL
production	NULL
,	NULL
HL60	NULL
cells	NULL
treated	NULL
with	NULL
compounds	NULL
for	NULL
5	NULL
days	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/	NULL
ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cytochrome	NULL
c	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
,	NULL
62	NULL
T.	NULL
Hida	NULL
et	NULL
al	NULL
.	NULL

USA	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
,	NULL
the	NULL
change	NULL
of	NULL
absorbance	NULL
(	NULL
OD	NULL
550	NULL
nm	NULL
)	NULL
was	NULL
measured	NULL
,	NULL
and	NULL
the	NULL
quantity	NULL
of	NULL
superoxide	NULL
anion	NULL
production	NULL
per	NULL
cell	NULL
was	NULL
estimated	NULL
from	NULL
the	NULL
millimolar	NULL
extinction	NULL
coefficient	NULL
of	NULL
reduced	NULL
cytochrome	NULL
c	NULL
as	NULL
28.0	NULL
.	NULL

Detection	NULL
of	NULL
RARBG	NULL
mRNA	NULL
induction	NULL
HL60	NULL
cells	NULL
exposed	NULL
to	NULL
compounds	NULL
for	NULL
24	NULL
h	NULL
were	NULL
collected	NULL
and	NULL
washed	NULL
,	NULL
then	NULL
total	NULL
RNA	NULL
was	NULL
extracted	NULL
with	NULL
the	NULL
TRIzol	NULL
``	NULL
(	NULL
Gibco-BRL	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

RT-PCR	NULL
was	NULL
performed	NULL
with	NULL
an	NULL
RNA-PCR	NULL
kit	NULL
(	NULL
Perkin	NULL
Elmer	NULL
,	NULL
Branhburg	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
from	NULL
0.25	NULL
ug	NULL
of	NULL
total	NULL
RNA	NULL
,	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Primers	NULL
used	NULL
for	NULL
the	NULL
PCR	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
RARZ	NULL
sense	NULL
(	NULL
1-22	NULL
)	NULL
,	NULL
S-ATGTTTGACTGTATGGATGTTC-3	NULL
;	NULL
RAR	NULL
}	NULL
antisense	NULL
(	NULL
222-245	NULL
)	NULL
,	NULL
5-AAGCAGGGTTITGTA	NULL
CACTCG-3	NULL
'	NULL
;	NULL
human	NULL
P-actin	NULL
;	NULL
RT-PCR	NULL
Amplimer	NULL
Sets	NULL
(	NULL
Clontech	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

A	NULL
reaction	NULL
cycle	NULL
consisted	NULL
of	NULL
1	NULL
min	NULL
at	NULL
98°C	NULL
,	NULL
1	NULL
min	NULL
at	NULL
57°C	NULL
and	NULL
2	NULL
min	NULL
at	NULL
73°C	NULL
,	NULL
with	NULL
22	NULL
cycles	NULL
for	NULL
-actin	NULL
and	NULL
35	NULL
cycles	NULL
for	NULL
RAR3	NULL
.	NULL

A	NULL
10-wl	NULL
aliquot	NULL
of	NULL
each	NULL
reaction	NULL
sample	NULL
was	NULL
examined	NULL
on	NULL
1.5	NULL
%	NULL
agarose	NULL
gels	NULL
stained	NULL
with	NULL
ethidium	NULL
bromide	NULL
.	NULL

Table	NULL
1	NULL
.	NULL

Spleen	NULL
cell	NULL
culture	NULL
and	NULL
proliferation	NULL
assay	NULL
Spleen	NULL
cells	NULL
were	NULL
prepared	NULL
from	NULL
6-week-old	NULL
male	NULL
BALB/C	NULL
mice	NULL
as	NULL
reported	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
spleen	NULL
cells	NULL
were	NULL
suspended	NULL
at	NULL
6	NULL
x	NULL
10°/ml	NULL
in	NULL
RPMI1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FBS	NULL
and	NULL
50	NULL
wM	NULL
2-mercaptoethanol	NULL
;	NULL
and	NULL
0.2-ml	NULL
aliquots	NULL
were	NULL
plated	NULL
in	NULL
96-well	NULL
plates	NULL
and	NULL
then	NULL
cultured	NULL
with	NULL
5	NULL
ug/ml	NULL
of	NULL
E.	NULL
coli	NULL
LPS	NULL
(	NULL
Sigma	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
compound	NULL
.	NULL

After	NULL
3	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
pulsed	NULL
with	NULL
0.5	NULL
Ci	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
per	NULL
well	NULL
(	NULL
Amersham	NULL
,	NULL
Buck-inghamshire	NULL
,	NULL
UK	NULL
)	NULL
for	NULL
6	NULL
h	NULL
,	NULL
then	NULL
harvested	NULL
on	NULL
glass	NULL
filters	NULL
,	NULL
and	NULL
incorporated	NULL
radioactivity	NULL
was	NULL
counted	NULL
using	NULL
a	NULL
#	NULL
-plate	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
.	NULL

RESULTS	NULL
Characterization	NULL
of	NULL
compounds	NULL
used	NULL
in	NULL
this	NULL
study	NULL
Relative	NULL
binding	NULL
abilities	NULL
of	NULL
retinoid	NULL
compounds	NULL
are	NULL
comparably	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Namely	NULL
the	NULL
relative	NULL
binding	NULL
ability	NULL
was	NULL
calculated	NULL
from	NULL
the	NULL
ratio	NULL
of	NULL
ICs	NULL
,	NULL
of	NULL
a	NULL
compound	NULL
to	NULL
that	NULL
of	NULL
atRA	NULL
for	NULL
RAR	NULL
,	NULL
or	NULL
to	NULL
that	NULL
of	NULL
IcRA	NULL
for	NULL
RXR	NULL
.	NULL

ER-27191	NULL
,	NULL
which	NULL
we	NULL
showed	NULL
previously	NULL
to	NULL
be	NULL
an	NULL
RAR	NULL
antagonist	NULL
(	NULL
21	NULL
)	NULL
,	NULL
could	NULL
bind	NULL
to	NULL
RAR	NULL
,	NULL
#	NULL
and	NULL
y	NULL
with	NULL
relative	NULL
ICs	NULL
,	NULL
values	NULL
of	NULL
1.3	NULL
,	NULL
1.4	NULL
and	NULL
3.9	NULL
,	NULL
respectively	NULL
,	NULL
but	NULL
was	NULL
unable	NULL
to	NULL
Structure	NULL
,	NULL
binding	NULL
affinity	NULL
,	NULL
transactivational	NULL
activity	NULL
of	NULL
compounds	NULL
used	NULL
in	NULL
this	NULL
study	NULL
Compound	NULL
Structure	NULL
Binding	NULL
(	NULL
relative	NULL
IC	NULL
,	NULL
(	NULL
fold	NULL
)	NULL
)	NULL
Transactivation	NULL
(	NULL
relative	NULL
EDs	NULL
,	NULL
(	NULL
fold	NULL
)	NULL
)	NULL
RARa	NULL
RARB	NULL
RARy	NULL
RXRa	NULL
RARa	NULL
RARB	NULL
RARy	NULL
RXRa	NULL
atRA	NULL
RAR	NULL
agonist	NULL
IcRA	NULL
RAR/RXR	NULL
agonist	NULL
COOH	NULL
ER-27191	NULL
RAR	NULL
antagonist	NULL
ER-35795	NULL
RXR	NULL
agonist	NULL
LGD100754	NULL
RXR	NULL
homodimer	NULL
antagonist	NULL
o	NULL
Cs	NULL
(	NULL
RXR/RAR	NULL
heterodimer	NULL
agonist	NULL
)	NULL
coon	NULL
m	NULL
Jay	NULL
A	NULL
,	NULL
.	NULL

y	NULL
,	NULL
coon	NULL
-	NULL
1	NULL
1	NULL
1	NULL
43	NULL
1	NULL
1	NULL
1	NULL
17	NULL
-	NULL
-	NULL
-	NULL
6.6	NULL
-	NULL
1600	NULL
-	NULL
0.067	NULL
-	NULL
-	NULL
576	NULL
3.2	NULL
25	NULL
32	NULL
110	NULL
Relative	NULL
IC	NULL
;	NULL
,	NULL
values	NULL
and	NULL
ED	NULL
;	NULL
,	NULL
were	NULL
calculated	NULL
as	NULL
described	NULL
under	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

-	NULL
indicates	NULL
that	NULL
compounds	NULL
did	NULL
not	NULL
inhibit	NULL
specific	NULL
binding	NULL
(	NULL
less	NULL
than	NULL
25	NULL
%	NULL
inhibition	NULL
of	NULL
binding	NULL
)	NULL
of	NULL
labeled	NULL
atRA	NULL
or	NULL
I¢RA	NULL
even	NULL
at	NULL
a	NULL
500-fold	NULL
excess	NULL
or	NULL
showing	NULL
less	NULL
than	NULL
30	NULL
%	NULL
of	NULL
maximal	NULL
activity	NULL
at	NULL
3	NULL
uM	NULL
.	NULL

All	NULL
data	NULL
are	NULL
shown	NULL
as	NULL
the	NULL
mean	NULL
of	NULL
two	NULL
to	NULL
four	NULL
individual	NULL
experiments	NULL
.	NULL

RXR	NULL
Pathway	NULL
in	NULL
Cellular	NULL
Function	NULL
63	NULL
bind	NULL
to	NULL
RXR	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
high	NULL
binding	NULL
affinities	NULL
,	NULL
transactivational	NULL
activity	NULL
of	NULL
ER-27191	NULL
was	NULL
not	NULL
seen	NULL
in	NULL
any	NULL
RAR	NULL
sub-type	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
ER-35795	NULL
,	NULL
a	NULL
novel	NULL
synthetic	NULL
retin-oid	NULL
,	NULL
could	NULL
bind	NULL
strongly	NULL
to	NULL
RXR	NULL
with	NULL
a	NULL
similar	NULL
affinity	NULL
to	NULL
IcRA	NULL
and	NULL
enhanced	NULL
the	NULL
transactivation	NULL
,	NULL
but	NULL
did	NULL
not	NULL
bind	NULL
to	NULL
RARs	NULL
.	NULL

Thus	NULL
,	NULL
ER-35795	NULL
was	NULL
a	NULL
selective	NULL
agonist	NULL
for	NULL
RXR	NULL
.	NULL

LGD100754	NULL
,	NULL
reported	NULL
as	NULL
a	NULL
RXR	NULL
homodimer	NULL
antagonist	NULL
,	NULL
was	NULL
described	NULL
as	NULL
agonist	NULL
in	NULL
the	NULL
case	NULL
of	NULL
RXR/RAR	NULL
heterodimer	NULL
(	NULL
25	NULL
)	NULL
.	NULL

In	NULL
this	NULL
assay	NULL
system	NULL
,	NULL
LGD100754	NULL
actually	NULL
showed	NULL
agonistic	NULL
activity	NULL
for	NULL
RAR	NULL
,	NULL
but	NULL
did	NULL
not	NULL
induce	NULL
RXR/RXR	NULL
homodimer	NULL
transactivation	NULL
.	NULL

Effects	NULL
of	NULL
ER-27191	NULL
on	NULL
the	NULL
transactivation	NULL
by	NULL
retinoid	NULL
com	NULL
pounds	NULL
via	NULL
RAR	NULL
or	NULL
RXR	NULL
The	NULL
inhibitory	NULL
profile	NULL
of	NULL
ER-27191	NULL
on	NULL
transcriptional	NULL
|	NULL
RAR	NULL
a	NULL
PLAP	NULL
activity	NULL
(	NULL
RLU	NULL
)	NULL
0x100	NULL
<	NULL
'~\\wu|	NULL
mmmipoorrmrorrmro-rmr	NULL
--	NULL
-mm	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
10000	NULL
Concentration	NULL
of	NULL
ER-27191	NULL
(	NULL
nM	NULL
)	NULL
6x10+	NULL
§	NULL
RARB	NULL
5x104	NULL
-|	NULL
PLAP	NULL
activity	NULL
(	NULL
RLU	NULL
)	NULL
0X100__\	NULL
“	NULL
'	NULL
1	NULL
}	NULL
0	NULL
.	NULL

1	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
10000	NULL
Concentration	NULL
of	NULL
ER-27191	NULL
(	NULL
nM	NULL
)	NULL
activity	NULL
induced	NULL
by	NULL
10	NULL
nM	NULL
atRA	NULL
and	NULL
IcRA	NULL
was	NULL
examined	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
ER-27191	NULL
inhibited	NULL
the	NULL
transcriptional	NULL
activities	NULL
via	NULL
RARs	NULL
induced	NULL
by	NULL
both	NULL
atRA	NULL
and	NULL
IcRA	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
,	NULL
but	NULL
failed	NULL
to	NULL
inhibit	NULL
the	NULL
transcriptional	NULL
activities	NULL
via	NULL
RXR	NULL
induced	NULL
by	NULL
IcRA	NULL
or	NULL
ER-35795	NULL
,	NULL
an	NULL
RXR	NULL
agonist	NULL
.	NULL

In	NULL
the	NULL
only	NULL
RAR/3	NULL
transformant	NULL
,	NULL
ER-27191	NULL
itself	NULL
slightly	NULL
increased	NULL
the	NULL
transactivation	NULL
,	NULL
but	NULL
the	NULL
transactivation	NULL
induced	NULL
by	NULL
atRA	NULL
or	NULL
IcRA	NULL
was	NULL
suppressed	NULL
to	NULL
the	NULL
level	NULL
by	NULL
ER-27191	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
PH	NULL
]	NULL
9cRA	NULL
to	NULL
RARs	NULL
(	NULL
RAR	NULL
a	NULL
,	NULL
RAR/3	NULL
and	NULL
RAR	NULL
y	NULL
)	NULL
was	NULL
also	NULL
inhibited	NULL
by	NULL
ER-27191	NULL
;	NULL
however	NULL
,	NULL
ER-27191	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
[	NULL
PH	NULL
]	NULL
JI9cRA	NULL
to	NULL
RXR	NULL
a	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
showed	NULL
that	NULL
ER-27191	NULL
can	NULL
completely	NULL
inhibit	NULL
the	NULL
RAR	NULL
pathway	NULL
activated	NULL
not	NULL
only	NULL
by	NULL
atRA	NULL
,	NULL
but	NULL
also	NULL
by	NULL
IcRA	NULL
.	NULL

Thus	NULL
ER-27191	NULL
is	NULL
defined	NULL
as	NULL
a	NULL
pan-antagonist	NULL
for	NULL
RAR	NULL
.	NULL

X2	NULL
5x10+-	NULL
4x104	NULL
-|	NULL
PLAP	NULL
activity	NULL
(	NULL
RLU	NULL
)	NULL
1x104-	NULL
0X100__\§Q	NULL
“	NULL
‘	NULL
I	NULL
rrp	NULL
9	NULL
m	NULL
rm	NULL
r	NULL
rm	NULL
]	NULL
T	NULL
Tm	NULL
0	NULL
0	NULL
.	NULL

1	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
10000	NULL
Concentration	NULL
of	NULL
ER-27191	NULL
(	NULL
nM	NULL
)	NULL
RX	NULL
Ro	NULL
1	NULL
.	NULL

210°	NULL
.	NULL

0x10	NULL
``	NULL
8x104	NULL
6x104	NULL
PLAP	NULL
activity	NULL
(	NULL
RLU	NULL
)	NULL
ax104	NULL
2x104	NULL
0X1004L\\\	NULL
”	NULL
”	NULL
I	NULL
t	NULL
rere	NULL
f	NULL
Cmp	NULL
reap	NULL
emp	NULL
Cm	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
10000	NULL
Concentratlon	NULL
of	NULL
ER-27191	NULL
(	NULL
nM	NULL
)	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

-	NULL
Antagonistic	NULL
activity	NULL
of	NULL
ER-27191	NULL
towards	NULL
atRA-	NULL
,	NULL
IcRA-	NULL
or	NULL
ER-35795-induced	NULL
transcription	NULL
.	NULL

The	NULL
transformants	NULL
transfected	NULL
with	NULL
the	NULL
reporter	NULL
plasmid	NULL
CRBP	NULL
I-PLAP	NULL
(	NULL
RARa	NULL
,	NULL
/3	NULL
,	NULL
y	NULL
)	NULL
or	NULL
CRBP	NULL
II-PLAP	NULL
(	NULL
RXR	NULL
)	NULL
in	NULL
receptor-expressing	NULL
transformant	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
ER-27191	NULL
(	NULL
[	NULL
_	NULL
]	NULL
)	NULL
with	NULL
10	NULL
nM	NULL
atRA	NULL
(	NULL
MRD	NULL
)	NULL
,	NULL
10	NULL
nM	NULL
IcRA	NULL
(	NULL
@	NULL
)	NULL
,	NULL
or	NULL
10	NULL
nM	NULL
ER-35795	NULL
(	NULL
&	NULL
)	NULL
.	NULL

After	NULL
2	NULL
days	NULL
of	NULL
exposure	NULL
,	NULL
the	NULL
transcriptional	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
measuring	NULL
the	NULL
PLAP	NULL
activity	NULL
in	NULL
the	NULL
supernatant	NULL
of	NULL
the	NULL
cell	NULL
culture	NULL
.	NULL

Three	NULL
independent	NULL
experiments	NULL
were	NULL
done	NULL
,	NULL
and	NULL
representative	NULL
data	NULL
are	NULL
shown	NULL
.	NULL

64	NULL
T.	NULL
Hida	NULL
et	NULL
al	NULL
.	NULL

HL60	NULL
differentiation	NULL
induced	NULL
by	NULL
atRA	NULL
,	NULL
IcRA	NULL
and	NULL
RXR	NULL
agonist	NULL
By	NULL
using	NULL
the	NULL
compounds	NULL
characterized	NULL
above	NULL
,	NULL
we	NULL
next	NULL
examined	NULL
the	NULL
contributions	NULL
of	NULL
the	NULL
RAR	NULL
and	NULL
RXR	NULL
pathways	NULL
to	NULL
cell	NULL
function	NULL
,	NULL
especially	NULL
those	NULL
triggered	NULL
by	NULL
IcRA	NULL
and	NULL
the	NULL
selective	NULL
RXR	NULL
agonist	NULL
.	NULL

As	NULL
HL60	NULL
,	NULL
which	NULL
only	NULL
expresses	NULL
RARa	NULL
and	NULL
RXRa	NULL
,	NULL
differentiate	NULL
in	NULL
response	NULL
to	NULL
atRA	NULL
and	NULL
IcRA	NULL
(	NULL
12	NULL
,	NULL
26-31	NULL
)	NULL
,	NULL
we	NULL
chose	NULL
it	NULL
as	NULL
a	NULL
model	NULL
cell	NULL
for	NULL
our	NULL
purpose	NULL
.	NULL

First	NULL
,	NULL
the	NULL
HL60	NULL
differentiation	NULL
was	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
,	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
CD1	NULL
1b-positive	NULL
cells	NULL
was	NULL
determined	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
nM	NULL
atRA	NULL
or	NULL
IcRA	NULL
,	NULL
HL60	NULL
fully	NULL
expressed	NULL
CD11b	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
ER35795	NULL
,	NULL
an	NULL
RXR	NULL
agonist	NULL
,	NULL
which	NULL
lacks	NULL
binding	NULL
ability	NULL
with	NULL
RAR	NULL
and	NULL
has	NULL
no	NULL
inducing	NULL
activity	NULL
for	NULL
transactivation	NULL
through	NULL
RARs	NULL
,	NULL
also	NULL
increased	NULL
the	NULL
proportion	NULL
of	NULL
CD11b-positive	NULL
cells	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

Subsequently	NULL
,	NULL
100	NULL
(	NULL
A	NULL
)	NULL
(	NULL
B	NULL
)	NULL
co	NULL
T.	NULL
&	NULL
O	NULL
I	NULL
p	NULL
T	NULL
CD11b-positive	NULL
cells	NULL
(	NULL
%	NULL
)	NULL
20	NULL
0	NULL
r	NULL
--	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
6	NULL
(	NULL
C	NULL
)	NULL
0.01	NULL
0.1	NULL
1	NULL
10	NULL
100	NULL
100010000	NULL
Concentration	NULL
of	NULL
compound	NULL
(	NULL
nM	NULL
)	NULL
compound	NULL
cDNA	NULL
_	NULL
conc	NULL
.	NULL

(	NULL
M	NULL
)	NULL
RARB	NULL
B-actin	NULL
lane	NULL
ER-35795	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
|	NULL
superoxide	NULL
production	NULL
from	NULL
HL60	NULL
was	NULL
measured	NULL
in	NULL
terms	NULL
of	NULL
functional	NULL
cell	NULL
differentiation	NULL
.	NULL

Concomitantly	NULL
with	NULL
the	NULL
differentiation	NULL
of	NULL
HL60	NULL
cells	NULL
,	NULL
proliferation	NULL
was	NULL
decreased	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
proliferation	NULL
and	NULL
increase	NULL
of	NULL
CD1	NULL
1b	NULL
expression	NULL
were	NULL
accompanied	NULL
with	NULL
significant	NULL
elevation	NULL
of	NULL
superoxide	NULL
anion	NULL
production	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

This	NULL
functional	NULL
differentiation	NULL
was	NULL
induced	NULL
by	NULL
not	NULL
only	NULL
IcRA	NULL
,	NULL
but	NULL
also	NULL
the	NULL
RXR	NULL
agonist	NULL
ER-35795	NULL
.	NULL

Finally	NULL
it	NULL
was	NULL
examined	NULL
whether	NULL
these	NULL
differentiation	NULL
pathways	NULL
were	NULL
the	NULL
same	NULL
or	NULL
not	NULL
by	NULL
observing	NULL
RAR	NULL
transcription	NULL
.	NULL

It	NULL
is	NULL
known	NULL
that	NULL
the	NULL
RXR/RAR	NULL
dimer	NULL
can	NULL
up-regulate	NULL
the	NULL
mRNA	NULL
directly	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ligand	NULL
for	NULL
RAR	NULL
,	NULL
atRA	NULL
and	NULL
IcRA	NULL
,	NULL
because	NULL
RARE	NULL
exists	NULL
upstream	NULL
of	NULL
the	NULL
RAR/3	NULL
gene	NULL
(	NULL
32	NULL
-	NULL
34	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
induction	NULL
of	NULL
RAR/	NULL
#	NULL
mRNA	NULL
might	NULL
show	NULL
that	NULL
the	NULL
RAR	NULL
pathway	NULL
would	NULL
work	NULL
during	NULL
HL60	NULL
differentiation	NULL
.	NULL

In	NULL
HL6O0	NULL
cells	NULL
,	NULL
1	NULL
M	NULL
ER-35795	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
|_	NULL
9cRA	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
atRA	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
L	NULL
Control	NULL
|	NULL
1	NULL
P	NULL
T	NULL
P	NULL
POT	NULL
COT	NULL
OC	NULL
OT	NULL
Od	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
250	NULL
300	NULL
350	NULL
O	NULL
;	NULL
production	NULL
(	NULL
nmol	NULL
/	NULL
1x10	NULL
Scells	NULL
/	NULL
min	NULL
)	NULL
ER-27191	NULL
(	NULL
3	NULL
uM	NULL
)	NULL
atRA	NULL
9cRA	NULL
35795	NULL
27191	NULL
atRA	NULL
9cRA	NULL
35795	NULL
-	NULL
oe	NULL
marker	NULL
co	NULL
do	NULL
20	NULL
30°	NULL
40	NULL
5000600	NULL
70	NULL
8	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Differentiation	NULL
of	NULL
HL60	NULL
induced	NULL
by	NULL
RAR	NULL
and	NULL
RXR	NULL
agonists	NULL
.	NULL

A	NULL
:	NULL
Elevation	NULL
of	NULL
CD11b	NULL
induced	NULL
by	NULL
RAR	NULL
and	NULL
RXR	NULL
ligands	NULL
.	NULL

HL60	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
atRA	NULL
(	NULL
MB	NULL
)	NULL
,	NULL
IcRA	NULL
(	NULL
@	NULL
)	NULL
and	NULL
ER-35795	NULL
(	NULL
&	NULL
)	NULL
for	NULL
5	NULL
days	NULL
,	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
CD11b-positive	NULL
cells	NULL
was	NULL
measured	NULL
by	NULL
flow	NULL
cytometer	NULL
.	NULL

Three	NULL
separate	NULL
experiments	NULL
were	NULL
done	NULL
,	NULL
and	NULL
representative	NULL
data	NULL
are	NULL
shown	NULL
.	NULL

B	NULL
:	NULL
Cellular	NULL
function	NULL
induced	NULL
by	NULL
RAR	NULL
and	NULL
RXR	NULL
agonists	NULL
.	NULL

HL60	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
indicated	NULL
compounds	NULL
for	NULL
5	NULL
days	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stimulated	NULL
by	NULL
PMA	NULL
and	NULL
production	NULL
of	NULL
superoxide	NULL
anion	NULL
was	NULL
measured	NULL
in	NULL
terms	NULL
of	NULL
reduction	NULL
of	NULL
cytochrome	NULL
c.	NULL
Data	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
data	NULL
points	NULL
+	NULL
S.E.M	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
Student	NULL
's	NULL
t-test	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
was	NULL
considered	NULL
to	NULL
indicate	NULL
statistical	NULL
significance	NULL
)	NULL
.	NULL

C	NULL
:	NULL
Induction	NULL
of	NULL
RAR/	NULL
#	NULL
mRNA	NULL
.	NULL

HL60	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
the	NULL
compound	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
ER-27191	NULL
for	NULL
24	NULL
h.	NULL
Total	NULL
RNA	NULL
was	NULL
prepared	NULL
,	NULL
and	NULL
RT-PCR	NULL
was	NULL
performed	NULL
.	NULL

PCR	NULL
samples	NULL
were	NULL
examined	NULL
on	NULL
1.5	NULL
%	NULL
agarose	NULL
gels	NULL
and	NULL
stained	NULL
with	NULL
ethidium	NULL
bromide	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
detected	NULL
at	NULL
269	NULL
bp	NULL
for	NULL
RAR/3	NULL
and	NULL
849	NULL
bp	NULL
for	NULL
f-actin	NULL
.	NULL

Lane	NULL
c	NULL
:	NULL
amplified	NULL
from	NULL
cDNA	NULL
,	NULL
1	NULL
:	NULL
untreated	NULL
,	NULL
2	NULL
:	NULL
atRA	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
,	NULL
3	NULL
:	NULL
IcRA	NULL
(	NULL
1	NULL
M	NULL
)	NULL
,	NULL
4	NULL
:	NULL
ER-35795	NULL
(	NULL
1	NULL
M	NULL
)	NULL
,	NULL
5	NULL
:	NULL
ER-27191	NULL
(	NULL
3	NULL
uM	NULL
)	NULL
,	NULL
6	NULL
:	NULL
atRA	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
+	NULL
ER-27191	NULL
(	NULL
3	NULL
wM	NULL
)	NULL
,	NULL
7	NULL
:	NULL
IcRA	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
+	NULL
ER-27191	NULL
(	NULL
3	NULL
wM	NULL
)	NULL
,	NULL
8	NULL
:	NULL
ER-35795	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
+	NULL
ER-27191	NULL
(	NULL
3	NULL
wM	NULL
)	NULL
.	NULL

Three	NULL
independent	NULL
experiments	NULL
were	NULL
done	NULL
,	NULL
and	NULL
representative	NULL
data	NULL
are	NULL
shown	NULL
.	NULL

RXR	NULL
Pathway	NULL
in	NULL
Cellular	NULL
Function	NULL
65	NULL
atRA	NULL
could	NULL
induce	NULL
the	NULL
transcription	NULL
of	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
:	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
and	NULL
this	NULL
induction	NULL
was	NULL
diminished	NULL
by	NULL
cotreatment	NULL
with	NULL
3	NULL
M	NULL
ER-27191	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
RAR/Z3	NULL
mRNA	NULL
in	NULL
the	NULL
cells	NULL
treated	NULL
with	NULL
1	NULL
M	NULL
IcRA	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
was	NULL
not	NULL
so	NULL
prominent	NULL
,	NULL
even	NULL
though	NULL
the	NULL
extent	NULL
of	NULL
functional	NULL
cell	NULL
differentiation	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
with	NULL
1	NULL
uM	NULL
atRA	NULL
.	NULL

Furthermore	NULL
,	NULL
ER-35795	NULL
,	NULL
even	NULL
at	NULL
the	NULL
concentration	NULL
of	NULL
10	NULL
uM	NULL
,	NULL
failed	NULL
to	NULL
induce	NULL
RAR,3	NULL
transcription	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
RAR	NULL
and	NULL
RXR	NULL
antagonists	NULL
on	NULL
the	NULL
differentiation	NULL
of	NULL
HL6O	NULL
ER-27191	NULL
,	NULL
an	NULL
RAR-selective	NULL
antagonist	NULL
,	NULL
did	NULL
not	NULL
itself	NULL
affect	NULL
the	NULL
differentiation	NULL
of	NULL
HL60	NULL
,	NULL
but	NULL
suppressed	NULL
the	NULL
appearance	NULL
of	NULL
CD11b-positive	NULL
cells	NULL
induced	NULL
by	NULL
exposure	NULL
to	NULL
10	NULL
nM	NULL
atRA	NULL
or	NULL
IcRA	NULL
,	NULL
with	NULL
similar	NULL
dose	NULL
dependence	NULL
in	NULL
each	NULL
case	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
when	NULL
a	NULL
higher	NULL
ligand	NULL
concentration	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
was	NULL
employed	NULL
,	NULL
ER-27191	NULL
inhibited	NULL
the	NULL
HL60	NULL
differentiation	NULL
induced	NULL
by	NULL
atRA	NULL
,	NULL
but	NULL
the	NULL
inhibitory	NULL
effect	NULL
on	NULL
the	NULL
differentiation	NULL
induced	NULL
by	NULL
IcRA	NULL
was	NULL
apparently	NULL
diminished	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

As	NULL
in	NULL
the	NULL
case	NULL
of	NULL
10	NULL
or	NULL
100	NULL
nM	NULL
,	NULL
ER-35795	NULL
was	NULL
not	NULL
inhibited	NULL
at	NULL
all	NULL
by	NULL
ER-27191	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

To	NULL
clarify	NULL
the	NULL
pathways	NULL
activated	NULL
by	NULL
each	NULL
ligand	NULL
,	NULL
ER-27191	NULL
,	NULL
an	NULL
antagonist	NULL
for	NULL
RAR	NULL
,	NULL
and	NULL
LGD100754	NULL
,	NULL
an	NULL
RXR	NULL
homodimer	NULL
antagonist	NULL
,	NULL
were	NULL
used	NULL
in	NULL
the	NULL
HL60	NULL
differentiation	NULL
system	NULL
.	NULL

LGD100754	NULL
was	NULL
reported	NULL
to	NULL
have	NULL
antagonist	NULL
activity	NULL
in	NULL
RXR/RXR	NULL
homodimer	NULL
transactivation	NULL
,	NULL
but	NULL
it	NULL
turned	NULL
into	NULL
an	NULL
activator	NULL
of	NULL
the	NULL
RXR/RAR	NULL
heterodimers	NULL
(	NULL
25	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
LGD100754	NULL
partially	NULL
induced	NULL
CD11b	NULL
expression	NULL
on	NULL
the	NULL
HL6O0	NULL
cell	NULL
surface	NULL
,	NULL
and	NULL
this	NULL
activity	NULL
(	NULL
A	NULL
)	NULL
100-	NULL
1007	NULL
#	NULL
p	NULL
804	NULL
so	NULL
;	NULL
3	NULL
$	NULL
=	NULL
ly	NULL
a	NULL
5	NULL
so	NULL
.	NULL

®	NULL
so-	NULL
8	NULL
so-E	NULL
H	NULL
2	NULL
40	NULL
&	NULL
407	NULL
f	NULL
|	NULL
z	NULL
0	NULL
-	NULL
le	NULL
8	NULL
20	NULL
20-o—§\	NULL
7	NULL
or	NULL
o	NULL
``	NULL
b.o1	NULL
o1	NULL
1	NULL
10	NULL
100	NULL
100010000	NULL
0	NULL
©0.01	NULL
0.4	NULL
Concentration	NULL
of	NULL
ER-27191	NULL
(	NULL
nM	NULL
)	NULL
ronin	NULL
fp	NULL
woes	NULL
.	NULL

99	NULL
%	NULL
ity	NULL
BJ	NULL
a	NULL
ubc	NULL
Concentration	NULL
of	NULL
ER-27191	NULL
(	NULL
nM	NULL
)	NULL
seemed	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
RXR/RAR	NULL
heterodimer	NULL
activation	NULL
,	NULL
because	NULL
it	NULL
was	NULL
antagonized	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
M	NULL
ER-27191	NULL
,	NULL
an	NULL
RAR	NULL
antagonist	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

The	NULL
RAR	NULL
antagonist-resistant	NULL
activities	NULL
induced	NULL
by	NULL
the	NULL
ER-35795	NULL
and	NULL
by	NULL
a	NULL
high	NULL
dose	NULL
of	NULL
IcRA	NULL
were	NULL
both	NULL
inhibited	NULL
by	NULL
the	NULL
RXR/RXR	NULL
homodimer	NULL
antagonist	NULL
,	NULL
LGD100754	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
RAR	NULL
antagonist	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
co-treatment	NULL
of	NULL
LGD100754	NULL
with	NULL
RAR	NULL
antagonist	NULL
extracted	NULL
the	NULL
RXR	NULL
homodimer	NULL
antagonistic	NULL
activity	NULL
of	NULL
LGD100754	NULL
in	NULL
cellular	NULL
response	NULL
.	NULL

These	NULL
data	NULL
strongly	NULL
suggest	NULL
that	NULL
two	NULL
pathways	NULL
exist	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
HL60	NULL
differentiation	NULL
:	NULL
1	NULL
)	NULL
an	NULL
RAR-antagonist-inhibitable	NULL
RAR-dependent	NULL
pathway	NULL
and	NULL
2	NULL
)	NULL
an	NULL
RXR-antagonist-inhibitable	NULL
RXR-dependent	NULL
pathway	NULL
,	NULL
which	NULL
is	NULL
RAR-independent	NULL
.	NULL

Effects	NULL
of	NULL
retinoids	NULL
on	NULL
the	NULL
proliferation	NULL
of	NULL
splenocytes	NULL
Since	NULL
atRA	NULL
and	NULL
IcRA	NULL
inhibit	NULL
B	NULL
cell	NULL
proliferation	NULL
induced	NULL
by	NULL
LPS	NULL
(	NULL
24	NULL
,	NULL
35	NULL
)	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
the	NULL
putative	NULL
RAR-dependent	NULL
and	NULL
RXR-dependent	NULL
pathways	NULL
are	NULL
functional	NULL
in	NULL
normal	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
atRA	NULL
and	NULL
IcRA	NULL
both	NULL
inhibited	NULL
the	NULL
proliferation	NULL
of	NULL
spleen	NULL
cells	NULL
.	NULL

ER-27191	NULL
,	NULL
an	NULL
RAR	NULL
antagonist	NULL
,	NULL
alone	NULL
did	NULL
not	NULL
show	NULL
any	NULL
inhibition	NULL
up	NULL
to	NULL
100	NULL
nM	NULL
.	NULL

Interestingly	NULL
,	NULL
ER-35795	NULL
,	NULL
an	NULL
RXR	NULL
agonist	NULL
,	NULL
could	NULL
also	NULL
inhibit	NULL
the	NULL
splenocyte	NULL
proliferation	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10	NULL
nM	NULL
or	NULL
higher	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
B	NULL
cell	NULL
growth	NULL
induced	NULL
by	NULL
10	NULL
nM	NULL
atRA	NULL
or	NULL
IcRA	NULL
was	NULL
completely	NULL
reversed	NULL
by	NULL
100	NULL
nM	NULL
ER-27191	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
know	NULL
which	NULL
pathway	NULL
is	NULL
contributing	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
ER35795	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
LGD100754	NULL
.	NULL

Consistent	NULL
(	NULL
B	NULL
)	NULL
(	NULL
C	NULL
)	NULL
60	NULL
te	NULL
...	NULL
CD11b-positive	NULL
cells	NULL
(	NULL
%	NULL
)	NULL
33	NULL
|	NULL
ho	NULL
O	NULL
|	NULL
A	NULL
10	NULL
100	NULL
100010000	NULL
0	NULL
1	NULL
10	NULL
100	NULL
Concentration	NULL
of	NULL
LGD100754	NULL
(	NULL
nM	NULL
)	NULL
1000	NULL
10000	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Inhibitory	NULL
effects	NULL
of	NULL
ER-27191	NULL
and	NULL
LGD100754	NULL
on	NULL
HL60	NULL
differentiation	NULL
induced	NULL
by	NULL
atRA	NULL
or	NULL
IcRA	NULL
and	NULL
RXR	NULL
agonist	NULL
.	NULL

A	NULL
and	NULL
B	NULL
:	NULL
HL60	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
ER-27191	NULL
(	NULL
[	NULL
_	NULL
]	NULL
)	NULL
;	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
nM	NULL
atRA	NULL
(	NULL
MRD	NULL
,	NULL
IcRA	NULL
(	NULL
@	NULL
)	NULL
or	NULL
ER-35795	NULL
(	NULL
&	NULL
)	NULL
(	NULL
A	NULL
)	NULL
;	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
nM	NULL
atRA	NULL
(	NULL
MBD	NULL
,	NULL
IcRA	NULL
(	NULL
@	NULL
)	NULL
or	NULL
ER-35795	NULL
(	NULL
&	NULL
)	NULL
(	NULL
B	NULL
)	NULL
.	NULL

C	NULL
:	NULL
HL60	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
LGD100754	NULL
(	NULL
@	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
wM	NULL
ER-27191	NULL
(	NULL
<	NULL
>	NULL
)	NULL
,	NULL
100	NULL
nM	NULL
IcRA	NULL
(	NULL
@	NULL
)	NULL
,	NULL
100	NULL
nM	NULL
IcRA	NULL
and	NULL
1	NULL
M	NULL
ER-27191	NULL
(	NULL
C	NULL
)	NULL
)	NULL
,	NULL
or	NULL
30	NULL
nM	NULL
ER-35795	NULL
and	NULL
1	NULL
M	NULL
ER-27191	NULL
(	NULL
A\	NULL
)	NULL
.	NULL

The	NULL
extent	NULL
of	NULL
cell	NULL
differentiation	NULL
was	NULL
measured	NULL
in	NULL
terms	NULL
of	NULL
the	NULL
percentage	NULL
of	NULL
CD11b-positive	NULL
cells	NULL
measured	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Three	NULL
separate	NULL
experiments	NULL
were	NULL
done	NULL
,	NULL
and	NULL
repre-	NULL
sentative	NULL
data	NULL
are	NULL
shown	NULL
.	NULL

66	NULL
T.	NULL
Hida	NULL
et	NULL
al	NULL
.	NULL

5x10	NULL
-	NULL
LPS	NULL
(	NULL
+	NULL
)	NULL
120	NULL
3	NULL
aid	NULL
5	NULL
|	NULL
E	NULL
§	NULL
3x10	NULL
Bs	NULL
E	NULL
{	NULL
e	NULL
``	NULL
3	NULL
8	NULL
.	NULL

€	NULL
_	NULL
e	NULL
§	NULL
2x10	NULL
3	NULL
]	NULL
a	NULL
To	NULL
1x10	NULL
]	NULL
0	NULL
R-	NULL
Q-	NULL
,	NULL
o	NULL
o	NULL
e	NULL
0	NULL
%	NULL
oor	NULL
or	NULL
_	NULL
i	NULL
_	NULL
i0	NULL
_	NULL
100	NULL
Concentration	NULL
of	NULL
compound	NULL
(	NULL
nM	NULL
)	NULL
LGD100754	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
-	NULL
~	NULL
+	NULL
+	NULL
~	NULL
+	NULL
~	NULL
+	NULL
ER-35795	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
_-	NULL
-	NULL
=	NULL
=-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Effects	NULL
of	NULL
compounds	NULL
on	NULL
LPS-stimulated	NULL
splenocyte	NULL
proliferation	NULL
.	NULL

A	NULL
:	NULL
Inhibitory	NULL
effects	NULL
of	NULL
compounds	NULL
on	NULL
LPS-stimulated	NULL
splenocyte	NULL
proliferation	NULL
.	NULL

Murine	NULL
spleen	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
atRA	NULL
(	NULL
RB	NULL
)	NULL
,	NULL
IcRA	NULL
(	NULL
@	NULL
)	NULL
,	NULL
ER-35795	NULL
(	NULL
&	NULL
)	NULL
or	NULL
ER-27191	NULL
(	NULL
[	NULL
_	NULL
]	NULL
)	NULL
.	NULL

Two	NULL
separate	NULL
experiments	NULL
were	NULL
done	NULL
,	NULL
and	NULL
similar	NULL
results	NULL
were	NULL
obtained	NULL
.	NULL

B	NULL
:	NULL
Reverse	NULL
of	NULL
proliferation	NULL
by	NULL
LGD100754	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
with	NULL
ER-35795	NULL
in	NULL
the	NULL
indicated	NULL
combination	NULL
of	NULL
ER-27191	NULL
and	NULL
LGD100754	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
data	NULL
points	NULL
+	NULL
S.E.M	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
Student	NULL
's	NULL
#	NULL
-test	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
was	NULL
con	NULL
sidered	NULL
to	NULL
indicate	NULL
statistical	NULL
significance	NULL
)	NULL
.	NULL

with	NULL
the	NULL
results	NULL
of	NULL
the	NULL
HL60	NULL
assay	NULL
,	NULL
LGD100754	NULL
also	NULL
inhibited	NULL
LPS-induced	NULL
B	NULL
cell	NULL
proliferation	NULL
,	NULL
but	NULL
it	NULL
was	NULL
reversed	NULL
by	NULL
ER-27191	NULL
,	NULL
an	NULL
RAR	NULL
antagonist	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
although	NULL
inhibition	NULL
of	NULL
the	NULL
response	NULL
by	NULL
100	NULL
nM	NULL
ER35795	NULL
,	NULL
an	NULL
RXR	NULL
agonist	NULL
,	NULL
was	NULL
not	NULL
reversed	NULL
by	NULL
only	NULL
ER-27191	NULL
and	NULL
LGD100754	NULL
,	NULL
but	NULL
it	NULL
was	NULL
reversed	NULL
by	NULL
both	NULL
antagonists	NULL
in	NULL
combination	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

DISCUSSION	NULL
ER-27191	NULL
was	NULL
found	NULL
to	NULL
be	NULL
an	NULL
antagonist	NULL
of	NULL
atRA-induced	NULL
HL60	NULL
cell	NULL
differentiation	NULL
(	NULL
21	NULL
,	NULL
26	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
ER-27191	NULL
exhibited	NULL
strong	NULL
binding	NULL
affinity	NULL
for	NULL
all	NULL
RAR-subtypes	NULL
,	NULL
while	NULL
it	NULL
failed	NULL
to	NULL
bind	NULL
to	NULL
RXR	NULL
.	NULL

Furthermore	NULL
,	NULL
ER-27191	NULL
antagonized	NULL
the	NULL
transactivation	NULL
of	NULL
RAR	NULL
a	NULL
,	NULL
#	NULL
and	NULL
y	NULL
transformants	NULL
induced	NULL
by	NULL
not	NULL
only	NULL
atRA	NULL
,	NULL
but	NULL
also	NULL
IcRA	NULL
,	NULL
although	NULL
it	NULL
can	NULL
not	NULL
inhibit	NULL
the	NULL
RXR	NULL
a	NULL
transactivation	NULL
induced	NULL
by	NULL
IcRA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

This	NULL
antagonistic	NULL
activity	NULL
of	NULL
ER-27191	NULL
correlated	NULL
with	NULL
the	NULL
ability	NULL
to	NULL
displace	NULL
[	NULL
'HJatRA	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
or	NULL
[	NULL
PH	NULL
]	NULL
IcRA	NULL
bound	NULL
to	NULL
RAR	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
ER-27191	NULL
binds	NULL
to	NULL
the	NULL
common	NULL
region	NULL
of	NULL
RARs	NULL
recognized	NULL
by	NULL
atRA	NULL
and	NULL
IcRA	NULL
.	NULL

It	NULL
is	NULL
well	NULL
known	NULL
that	NULL
atRA	NULL
induces	NULL
differentiation	NULL
of	NULL
HL60	NULL
cells	NULL
to	NULL
granulocytes	NULL
and	NULL
subsequently	NULL
causes	NULL
cell	NULL
death	NULL
by	NULL
apoptosis	NULL
mediated	NULL
by	NULL
RAR	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
the	NULL
role	NULL
of	NULL
RXR	NULL
ligand	NULL
during	NULL
HL60	NULL
differentiation	NULL
was	NULL
thought	NULL
to	NULL
be	NULL
a	NULL
synergistic	NULL
enhancer	NULL
of	NULL
RAR	NULL
activity	NULL
(	NULL
12	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
existence	NULL
of	NULL
an	NULL
RAR-independent	NULL
RXR	NULL
path	NULL
way	NULL
was	NULL
recently	NULL
reported	NULL
;	NULL
eg	NULL
.	NULL

,	NULL
antagonist-resistant	NULL
differentiation	NULL
and	NULL
apoptosis	NULL
induced	NULL
by	NULL
IcRA	NULL
(	NULL
26	NULL
)	NULL
,	NULL
apoptosis	NULL
in	NULL
HL60	NULL
cells	NULL
induced	NULL
by	NULL
an	NULL
RXR	NULL
agonist	NULL
(	NULL
27	NULL
)	NULL
,	NULL
and	NULL
RAR-independent	NULL
NB4	NULL
(	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
)	NULL
maturation	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
RXR	NULL
ligand	NULL
can	NULL
induce	NULL
HL60	NULL
differentiation	NULL
and	NULL
that	NULL
this	NULL
may	NULL
occur	NULL
through	NULL
an	NULL
RXR	NULL
pathway	NULL
.	NULL

This	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
following	NULL
findings	NULL
.	NULL

First	NULL
,	NULL
the	NULL
RXR	NULL
agonist	NULL
,	NULL
ER-35795	NULL
,	NULL
could	NULL
fully	NULL
induce	NULL
CD11b	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
and	NULL
cell	NULL
function	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

This	NULL
differentiation	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
ER-27191	NULL
,	NULL
an	NULL
RARs-selective	NULL
antagonist	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
:	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
RAR	NULL
antagonist	NULL
,	NULL
the	NULL
differentiation	NULL
induced	NULL
by	NULL
the	NULL
RXR	NULL
agonist	NULL
was	NULL
antagonized	NULL
by	NULL
LGD100754	NULL
,	NULL
an	NULL
RXR-homodimer	NULL
antagonist	NULL
,	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

The	NULL
purpose	NULL
of	NULL
combining	NULL
LGD100754	NULL
with	NULL
RAR	NULL
antagonist	NULL
was	NULL
to	NULL
eliminate	NULL
the	NULL
agonistic	NULL
action	NULL
of	NULL
LGD100754	NULL
via	NULL
RXR/RAR	NULL
heterodimer	NULL
,	NULL
as	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
LGD100754	NULL
itself	NULL
has	NULL
RXR/RAR	NULL
and	NULL
RXR/PPAR	NULL
agonistic	NULL
activities	NULL
(	NULL
25	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
we	NULL
observed	NULL
the	NULL
agonistic	NULL
activity	NULL
of	NULL
the	NULL
LGD100754	NULL
in	NULL
HL60	NULL
differentiation	NULL
,	NULL
and	NULL
found	NULL
that	NULL
this	NULL
effect	NULL
was	NULL
diminished	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
RAR	NULL
antagonist	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
RAR	NULL
antagonist	NULL
,	NULL
LGD100754	NULL
works	NULL
as	NULL
a	NULL
pure	NULL
RXR	NULL
antagonist	NULL
with	NULL
no	NULL
HL60	NULL
differentiation	NULL
.	NULL

This	NULL
is	NULL
the	NULL
first	NULL
time	NULL
that	NULL
LGD100754	NULL
manifests	NULL
its	NULL
RXR	NULL
homodimer	NULL
antagonistic	NULL
activity	NULL
in	NULL
cellular	NULL
response	NULL
combined	NULL
with	NULL
an	NULL
RAR	NULL
antagonist	NULL
.	NULL

Second	NULL
,	NULL
mRNA	NULL
is	NULL
RXR	NULL
Pathway	NULL
in	NULL
Cellular	NULL
Function	NULL
67	NULL
known	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
atRA	NULL
itself	NULL
through	NULL
RARE	NULL
existing	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
RAR/	NULL
#	NULL
gene	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

During	NULL
the	NULL
differentiation	NULL
of	NULL
HL60	NULL
,	NULL
it	NULL
was	NULL
found	NULL
that	NULL
atRA	NULL
induced	NULL
the	NULL
transcription	NULL
of	NULL
RAR/	NULL
mRNA	NULL
,	NULL
and	NULL
this	NULL
induction	NULL
was	NULL
weakened	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
RAR	NULL
antagonist	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
:	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
atRA	NULL
,	NULL
the	NULL
RXR	NULL
agonist	NULL
failed	NULL
to	NULL
induce	NULL
transcription	NULL
of	NULL
RARZ3	NULL
mRNA	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
even	NULL
though	NULL
it	NULL
induced	NULL
the	NULL
differentiation	NULL
of	NULL
HL60	NULL
,	NULL
again	NULL
suggesting	NULL
that	NULL
ER-35795	NULL
,	NULL
an	NULL
RXR	NULL
agonist	NULL
,	NULL
induced	NULL
HL60	NULL
differentiation	NULL
not	NULL
through	NULL
an	NULL
RAR-dependent	NULL
,	NULL
RARE-medi-ated	NULL
pathway	NULL
involving	NULL
induction	NULL
of	NULL
RAR/Z3	NULL
mRNA	NULL
,	NULL
but	NULL
through	NULL
another	NULL
pathway	NULL
that	NULL
is	NULL
not	NULL
accompanied	NULL
with	NULL
induction	NULL
of	NULL
RAR/	NULL
#	NULL
mRNA	NULL
.	NULL

As	NULL
reported	NULL
by	NULL
Apfel	NULL
et	NULL
al	NULL
.	NULL

(	NULL
12	NULL
)	NULL
,	NULL
HL60	NULL
differentiation	NULL
was	NULL
induced	NULL
not	NULL
only	NULL
by	NULL
atRA	NULL
or	NULL
IcRA	NULL
,	NULL
but	NULL
also	NULL
by	NULL
the	NULL
RXR	NULL
agonist	NULL
.	NULL

The	NULL
report	NULL
described	NULL
that	NULL
the	NULL
RXR	NULL
agonists	NULL
enhanced	NULL
the	NULL
RXR/RAR	NULL
heterodimer	NULL
,	NULL
even	NULL
though	NULL
RXR/RXR	NULL
homodimer	NULL
was	NULL
also	NULL
formed	NULL
by	NULL
RXR	NULL
ligand	NULL
on	NULL
retinoid	NULL
X	NULL
responsive	NULL
element	NULL
.	NULL

In	NULL
many	NULL
cases	NULL
,	NULL
the	NULL
role	NULL
of	NULL
RXR	NULL
compound	NULL
was	NULL
explained	NULL
by	NULL
enhancement	NULL
of	NULL
heterodimer	NULL
with	NULL
RAR	NULL
,	NULL
PPAR	NULL
and	NULL
the	NULL
like	NULL
.	NULL

However	NULL
,	NULL
the	NULL
results	NULL
described	NULL
here	NULL
suggest	NULL
the	NULL
possibility	NULL
that	NULL
high	NULL
concentrations	NULL
of	NULL
RXR	NULL
agonists	NULL
induce	NULL
the	NULL
RXR	NULL
/RXR	NULL
homodimer	NULL
pathway	NULL
.	NULL

Recently	NULL
the	NULL
possibility	NULL
was	NULL
also	NULL
reported	NULL
that	NULL
an	NULL
RAR-independent	NULL
RXR	NULL
signal	NULL
exists	NULL
in	NULL
atRA-sensitive	NULL
and	NULL
resistant	NULL
NB4	NULL
for	NULL
cell	NULL
maturation	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
it	NULL
is	NULL
strongly	NULL
suggested	NULL
that	NULL
a	NULL
functional	NULL
RXR	NULL
pathway	NULL
exists	NULL
for	NULL
myeloidal	NULL
cell	NULL
differentiation	NULL
mediated	NULL
by	NULL
RXR	NULL
homodimer	NULL
.	NULL

IcRA	NULL
is	NULL
also	NULL
known	NULL
to	NULL
induce	NULL
HL60	NULL
differentiation	NULL
(	NULL
26	NULL
,	NULL
31	NULL
)	NULL
.	NULL

From	NULL
the	NULL
results	NULL
shown	NULL
here	NULL
,	NULL
IcRA	NULL
bound	NULL
to	NULL
RXR	NULL
and	NULL
activated	NULL
RXR	NULL
-dependent	NULL
transcription	NULL
,	NULL
supporting	NULL
the	NULL
idea	NULL
that	NULL
IcRA	NULL
is	NULL
a	NULL
natural	NULL
ligand	NULL
for	NULL
RXR	NULL
(	NULL
36	NULL
)	NULL
.	NULL

However	NULL
,	NULL
ICRA	NULL
causes	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
HL60	NULL
predominantly	NULL
not	NULL
through	NULL
the	NULL
RXR	NULL
pathway	NULL
,	NULL
but	NULL
rather	NULL
through	NULL
the	NULL
RAR	NULL
pathway	NULL
at	NULL
a	NULL
dose	NULL
of	NULL
10	NULL
nM	NULL
or	NULL
less	NULL
,	NULL
because	NULL
the	NULL
differentiation	NULL
was	NULL
almost	NULL
completely	NULL
blocked	NULL
by	NULL
ER-27191	NULL
,	NULL
an	NULL
RARs-selective	NULL
antagonist	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
the	NULL
HL60	NULL
differentiation	NULL
induced	NULL
by	NULL
a	NULL
high	NULL
concentration	NULL
(	NULL
such	NULL
as	NULL
100	NULL
nM	NULL
)	NULL
of	NULL
IcRA	NULL
,	NULL
was	NULL
not	NULL
antagonized	NULL
by	NULL
ER-27191	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

It	NULL
was	NULL
reported	NULL
that	NULL
not	NULL
only	NULL
atRA	NULL
but	NULL
also	NULL
ICRA	NULL
could	NULL
induce	NULL
RAR/3	NULL
transcription	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

In	NULL
HL60	NULL
cells	NULL
,	NULL
10	NULL
nM	NULL
of	NULL
IcRA	NULL
could	NULL
induce	NULL
RAR/3	NULL
transcription	NULL
like	NULL
atRA	NULL
can	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
;	NULL
however	NULL
,	NULL
induction	NULL
of	NULL
RAR/3	NULL
mRNA	NULL
by	NULL
1	NULL
wM	NULL
of	NULL
IcRA	NULL
was	NULL
less	NULL
than	NULL
that	NULL
by	NULL
the	NULL
same	NULL
concentration	NULL
of	NULL
atRA	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
such	NULL
a	NULL
high	NULL
concentration	NULL
of	NULL
IcRA	NULL
might	NULL
change	NULL
the	NULL
differentia-tion-pathway	NULL
from	NULL
the	NULL
RAR-dependent	NULL
pathway	NULL
to	NULL
an	NULL
RXR	NULL
pathway	NULL
that	NULL
is	NULL
not	NULL
functionally	NULL
antagonized	NULL
by	NULL
ER-27191	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
more	NULL
than	NULL
100	NULL
nM	NULL
IcRA	NULL
,	NULL
it	NULL
was	NULL
also	NULL
reported	NULL
that	NULL
RXR	NULL
homodimer	NULL
formation	NULL
was	NULL
induced	NULL
(	NULL
12	NULL
)	NULL
.	NULL

From	NULL
kinetic	NULL
analysis	NULL
,	NULL
it	NULL
was	NULL
reported	NULL
that	NULL
RXR	NULL
exists	NULL
as	NULL
a	NULL
tetramer	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
ligand	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

RXR	NULL
tetramer	NULL
dissociates	NULL
to	NULL
RXR	NULL
homodimer	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IcRA	NULL
,	NULL
and	NULL
subsequently	NULL
RAR	NULL
and	NULL
cognate	NULL
ligand	NULL
induce	NULL
RXR/	NULL
RAR	NULL
heterodimer	NULL
.	NULL

Since	NULL
a	NULL
significant	NULL
fraction	NULL
of	NULL
the	NULL
dimer	NULL
remains	NULL
as	NULL
a	NULL
RXR	NULL
homodimer	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
high	NULL
concentration	NULL
of	NULL
IcRA	NULL
preferably	NULL
activates	NULL
RXR	NULL
homodimer	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
as	NULL
the	NULL
inhibitory	NULL
profile	NULL
of	NULL
RAR	NULL
antagonist	NULL
on	NULL
the	NULL
differentiation	NULL
of	NULL
HL60	NULL
induced	NULL
by	NULL
10	NULL
nM	NULL
or	NULL
100	NULL
nM	NULL
IcRA	NULL
was	NULL
also	NULL
quite	NULL
different	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
the	NULL
activation	NULL
pathway	NULL
is	NULL
dramatically	NULL
switched	NULL
from	NULL
RAR	NULL
to	NULL
RXR	NULL
depending	NULL
on	NULL
the	NULL
concentration	NULL
of	NULL
IcRA	NULL
employed	NULL
.	NULL

To	NULL
elucidate	NULL
possible	NULL
involvement	NULL
of	NULL
an	NULL
RXR	NULL
pathway	NULL
,	NULL
we	NULL
considered	NULL
a	NULL
similar	NULL
study	NULL
with	NULL
splenocytes	NULL
,	NULL
as	NULL
it	NULL
was	NULL
known	NULL
that	NULL
B	NULL
cell	NULL
proliferation	NULL
induced	NULL
by	NULL
mitogens	NULL
such	NULL
as	NULL
LPS	NULL
is	NULL
inhibited	NULL
by	NULL
atRA	NULL
,	NULL
mediating	NULL
RAR	NULL
a	NULL
(	NULL
24	NULL
)	NULL
.	NULL

It	NULL
was	NULL
also	NULL
shown	NULL
that	NULL
physiological	NULL
concentrations	NULL
of	NULL
atRA	NULL
and	NULL
IcRA	NULL
inhibit	NULL
the	NULL
growth	NULL
of	NULL
normal	NULL
human	NULL
and	NULL
murine	NULL
B	NULL
cells	NULL
(	NULL
35	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
the	NULL
proliferative	NULL
response	NULL
of	NULL
LPS-stimulated	NULL
splenocytes	NULL
was	NULL
suppressed	NULL
by	NULL
the	NULL
RXR	NULL
agonist	NULL
.	NULL

Thus	NULL
,	NULL
functional	NULL
activation	NULL
through	NULL
the	NULL
RXR	NULL
pathway	NULL
has	NULL
been	NULL
demonstrated	NULL
herein	NULL
by	NULL
an	NULL
effect	NULL
on	NULL
HL6O0	NULL
cell	NULL
differentiation	NULL
and	NULL
the	NULL
proliferative	NULL
response	NULL
of	NULL
LPS-stimulated	NULL
splenocyte	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
the	NULL
RXR-selective	NULL
agonist	NULL
induced	NULL
not	NULL
only	NULL
RXR	NULL
transactivation	NULL
,	NULL
but	NULL
also	NULL
granulocytic	NULL
differentiation	NULL
and	NULL
inhibition	NULL
of	NULL
splenocyte	NULL
proliferation	NULL
.	NULL

These	NULL
cellular	NULL
functions	NULL
were	NULL
not	NULL
antagonized	NULL
by	NULL
an	NULL
RAR-selective	NULL
antagonist	NULL
,	NULL
but	NULL
were	NULL
inhibited	NULL
by	NULL
an	NULL
RXR-homodimer	NULL
antagonist	NULL
,	NULL
while	NULL
its	NULL
agonistic	NULL
action	NULL
on	NULL
RAR	NULL
was	NULL
neutralized	NULL
by	NULL
an	NULL
RAR	NULL
antagonist	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
at	NULL
least	NULL
some	NULL
types	NULL
of	NULL
cells	NULL
retain	NULL
both	NULL
an	NULL
RAR-dependent	NULL
pathway	NULL
and	NULL
an	NULL
RXR-dependent	NULL
pathway	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
functionally	NULL
active	NULL
.	NULL

ICRA	NULL
can	NULL
utilize	NULL
both	NULL
pathways	NULL
,	NULL
depending	NULL
on	NULL
its	NULL
concentration	NULL
.	NULL

Although	NULL
RXR	NULL
had	NULL
been	NULL
thought	NULL
to	NULL
be	NULL
a	NULL
silent	NULL
receptor	NULL
,	NULL
we	NULL
showed	NULL
here	NULL
that	NULL
RXR	NULL
homodimer	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
RXR	NULL
ligands	NULL
.	NULL

Further	NULL
studies	NULL
combining	NULL
the	NULL
selective	NULL
activation	NULL
pathway	NULL
induced	NULL
by	NULL
RXR	NULL
homodimer	NULL
should	NULL
provide	NULL
new	NULL
insights	NULL
and	NULL
lead	NULL
to	NULL
novel	NULL
drug	NULL
discov-	NULL
ery	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Seiko	NULL
Higashi	NULL
for	NULL
expert	NULL
technical	NULL
assistance	NULL
and	NULL
Dr.	NULL
Makoto	NULL
Asada	NULL
for	NULL
his	NULL
support	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Dr.	NULL
Akira	NULL
Kakizuka	NULL
(	NULL
Osaka	NULL
Bioscience	NULL
Institute	NULL
)	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

REFERENCES	NULL
1	NULL
Sporn	NULL
MB	NULL
,	NULL
Roberts	NULL
AB	NULL
and	NULL
Goodman	NULL
DS	NULL
:	NULL
The	NULL
Retinoids	NULL
.	NULL

Biology	NULL
,	NULL
Chemistry	NULL
,	NULL
and	NULL
Medicine	NULL
,	NULL
2nd	NULL
Ed	NULL
,	NULL
Academic	NULL
Press	NULL
,	NULL
Orlando	NULL
,	NULL
FL	NULL
(	NULL
1992	NULL
)	NULL
2	NULL
Mangelsdorf	NULL
DJ	NULL
,	NULL
Thummel	NULL
C	NULL
,	NULL
Beato	NULL
M	NULL
,	NULL
Herlich	NULL
P	NULL
,	NULL
Schutz	NULL
G	NULL
,	NULL
Umesono	NULL
K	NULL
,	NULL
Blumberg	NULL
B	NULL
,	NULL
Kastner	NULL
P	NULL
,	NULL
Mark	NULL
M	NULL
,	NULL
Chambon	NULL
P	NULL
and	NULL
Evans	NULL
RM	NULL
:	NULL
The	NULL
nuclear	NULL
receptor	NULL
super	NULL
family	NULL
.	NULL

The	NULL
second	NULL
decade	NULL
.	NULL

Cell	NULL
83	NULL
,	NULL
835	NULL
-	NULL
839	NULL
(	NULL
1995	NULL
)	NULL
3	NULL
Bollag	NULL
W	NULL
:	NULL
The	NULL
retinoid	NULL
revolution	NULL
.	NULL

FASEB	NULL
J	NULL
10	NULL
,	NULL
938-939	NULL
(	NULL
1996	NULL
)	NULL
4	NULL
Levin	NULL
AA	NULL
,	NULL
Sturzenbecker	NULL
LJ	NULL
,	NULL
Kazmer	NULL
S	NULL
,	NULL
Bosakowski	NULL
T	NULL
,	NULL
68	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
19	NULL
T.	NULL
Hida	NULL
et	NULL
al	NULL
.	NULL

Huselton	NULL
C	NULL
,	NULL
Allenby	NULL
G	NULL
,	NULL
Speck	NULL
J	NULL
,	NULL
Kratzeisen	NULL
C	NULL
,	NULL
Rosenberger	NULL
M	NULL
,	NULL
Lovey	NULL
A	NULL
and	NULL
Grippo	NULL
JF	NULL
:	NULL
9-cis	NULL
Retinoic	NULL
acid	NULL
stereoisomer	NULL
binds	NULL
and	NULL
activates	NULL
the	NULL
nuclear	NULL
receptor	NULL
RXR	NULL
.	NULL

Nature	NULL
355	NULL
,	NULL
359	NULL
361	NULL
(	NULL
1992	NULL
)	NULL
Heyman	NULL
RA	NULL
,	NULL
Mangelsdorf	NULL
DJ	NULL
,	NULL
Dick	NULL
JA	NULL
,	NULL
Stein	NULL
RB	NULL
,	NULL
Eichele	NULL
G	NULL
,	NULL
Evans	NULL
RM	NULL
and	NULL
Thaller	NULL
C	NULL
:	NULL
9-cis	NULL
Retinoic	NULL
acid	NULL
is	NULL
a	NULL
high	NULL
affinity	NULL
ligand	NULL
for	NULL
the	NULL
retinoid	NULL
X	NULL
receptor	NULL
.	NULL

Cell	NULL
68	NULL
,	NULL
397-406	NULL
(	NULL
1992	NULL
)	NULL
Allenby	NULL
G	NULL
,	NULL
Bocquel	NULL
MT	NULL
,	NULL
Sanders	NULL
M	NULL
,	NULL
Kazmer	NULL
S	NULL
,	NULL
Speck	NULL
J	NULL
,	NULL
Rosenberger	NULL
M	NULL
,	NULL
Lovey	NULL
A	NULL
,	NULL
Kastner	NULL
P	NULL
,	NULL
Grippo	NULL
JF	NULL
,	NULL
Chambon	NULL
P	NULL
and	NULL
Levin	NULL
AA	NULL
:	NULL
Retinoic	NULL
acid	NULL
receptors	NULL
and	NULL
retinoid	NULL
X	NULL
receptors	NULL
interactions	NULL
with	NULL
endogenous	NULL
retinoic	NULL
acids	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
90	NULL
,	NULL
30	NULL
-	NULL
34	NULL
(	NULL
1993	NULL
)	NULL
Mukherjee	NULL
R	NULL
,	NULL
Davies	NULL
PJ	NULL
,	NULL
Crombie	NULL
DL	NULL
,	NULL
Bischoff	NULL
ED	NULL
,	NULL
Cesario	NULL
RM	NULL
,	NULL
Jow	NULL
L	NULL
,	NULL
Hamann	NULL
LG	NULL
,	NULL
Boehm	NULL
MF	NULL
,	NULL
Mondon	NULL
CE	NULL
,	NULL
Nadzan	NULL
AM	NULL
,	NULL
Paterniti	NULL
JRJ	NULL
and	NULL
Heyman	NULL
RA	NULL
:	NULL
Sensitization	NULL
of	NULL
diabetic	NULL
and	NULL
obese	NULL
mice	NULL
to	NULL
insulin	NULL
by	NULL
retinoid	NULL
X	NULL
receptor	NULL
agonists	NULL
.	NULL

Nature	NULL
386	NULL
,	NULL
407-410	NULL
(	NULL
1997	NULL
)	NULL
Westin	NULL
S	NULL
,	NULL
Kurokawa	NULL
R	NULL
,	NULL
Nolte	NULL
RT	NULL
,	NULL
Wisely	NULL
GB	NULL
,	NULL
McInerney	NULL
EM	NULL
,	NULL
Rose	NULL
DW	NULL
,	NULL
Milburn	NULL
MV	NULL
,	NULL
Rosenfeld	NULL
MG	NULL
and	NULL
Glass	NULL
CK	NULL
:	NULL
Interactions	NULL
controlling	NULL
the	NULL
assembly	NULL
of	NULL
nuclear-receptor	NULL
heterodimers	NULL
and	NULL
co-activators	NULL
.	NULL

Nature	NULL
395	NULL
,	NULL
199	NULL
-	NULL
202	NULL
(	NULL
1998	NULL
)	NULL
Forman	NULL
BM	NULL
,	NULL
Umesono	NULL
K	NULL
,	NULL
Chen	NULL
J	NULL
and	NULL
Evans	NULL
RM	NULL
:	NULL
Unique	NULL
response	NULL
pathways	NULL
are	NULL
established	NULL
by	NULL
allosteric	NULL
interactions	NULL
among	NULL
nuclear	NULL
hormone	NULL
receptors	NULL
.	NULL

Cell	NULL
81	NULL
,	NULL
541	NULL
-	NULL
550	NULL
(	NULL
1995	NULL
)	NULL
Leblanc	NULL
BP	NULL
and	NULL
Stunnenberg	NULL
G	NULL
:	NULL
9-cis	NULL
Retinoic	NULL
acid	NULL
signaling	NULL
changing	NULL
partners	NULL
causes	NULL
some	NULL
excitement	NULL
.	NULL

Genes	NULL
Dev	NULL
9	NULL
,	NULL
1811	NULL
1816	NULL
(	NULL
1996	NULL
)	NULL
Soontjens	NULL
CD	NULL
,	NULL
Rafter	NULL
JJ	NULL
and	NULL
Gustafsson	NULL
JA	NULL
:	NULL
Ligands	NULL
for	NULL
orphan	NULL
receptors	NULL
?	NULL

J	NULL
Endocrinol	NULL
150	NULL
,	NULL
$	NULL
241	NULL
-	NULL
$	NULL
257	NULL
(	NULL
1996	NULL
)	NULL
Apfel	NULL
CM	NULL
,	NULL
Kamber	NULL
M	NULL
,	NULL
Klau	NULL
M	NULL
,	NULL
Mohr	NULL
P	NULL
,	NULL
Keidel	NULL
S	NULL
and	NULL
LeMotte	NULL
PK	NULL
:	NULL
Enhancement	NULL
of	NULL
HL-60	NULL
differentiation	NULL
by	NULL
a	NULL
new	NULL
class	NULL
of	NULL
retinoids	NULL
with	NULL
selective	NULL
activity	NULL
on	NULL
retinoid	NULL
X	NULL
receptor	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270	NULL
,	NULL
30765	NULL
-	NULL
30772	NULL
(	NULL
1995	NULL
)	NULL
Benoit	NULL
G	NULL
,	NULL
Altucci	NULL
L	NULL
,	NULL
Flexor	NULL
M	NULL
,	NULL
Ruchaud	NULL
S	NULL
,	NULL
Lillehaug	NULL
J	NULL
,	NULL
Raffelsberger	NULL
W	NULL
,	NULL
Gronemeyer	NULL
H	NULL
and	NULL
Lenotte	NULL
M	NULL
:	NULL
RAR-independent	NULL
RXR	NULL
signaling	NULL
induced	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
leukemia	NULL
cell	NULL
maturation	NULL
.	NULL

EMBO	NULL
J	NULL
18	NULL
,	NULL
7011-7018	NULL
(	NULL
1999	NULL
)	NULL
Rosati	NULL
R	NULL
,	NULL
Ramnath	NULL
N	NULL
,	NULL
Adil	NULL
MR	NULL
,	NULL
Ou	NULL
X	NULL
,	NULL
Ali	NULL
MA	NULL
,	NULL
Heyman	NULL
RA	NULL
and	NULL
Kalemkerian	NULL
GP	NULL
:	NULL
Activity	NULL
of	NULL
9-cis-retinoic	NULL
acid	NULL
and	NULL
recep-tor-selective	NULL
retinoids	NULL
in	NULL
small	NULL
cell	NULL
lung	NULL
cancer	NULL
cell	NULL
lines	NULL
.	NULL

Anti-cancer	NULL
Res	NULL
18	NULL
,	NULL
4071-4075	NULL
(	NULL
1998	NULL
)	NULL
Na	NULL
SY	NULL
,	NULL
Kang	NULL
BY	NULL
,	NULL
Chung	NULL
SW	NULL
,	NULL
Han	NULL
SJ	NULL
,	NULL
Ma	NULL
X	NULL
,	NULL
Trinchieri	NULL
G	NULL
,	NULL
Im	NULL
SY	NULL
,	NULL
Lee	NULL
JW	NULL
and	NULL
Kim	NULL
TS	NULL
:	NULL
Retinoids	NULL
inhibit	NULL
interleukin-12	NULL
production	NULL
in	NULL
macrophages	NULL
through	NULL
physical	NULL
associations	NULL
of	NULL
retinoid	NULL
Xreceptor	NULL
and	NULL
NFkappaB	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
27	NULL
,	NULL
47674-47680	NULL
(	NULL
1999	NULL
)	NULL
Lenhard	NULL
JM	NULL
,	NULL
Lancaster	NULL
ME	NULL
,	NULL
Paulik	NULL
MA	NULL
,	NULL
Weiel	NULL
JE	NULL
,	NULL
Binz	NULL
JG	NULL
,	NULL
Sundseth	NULL
SS	NULL
,	NULL
Gaskill	NULL
BA	NULL
,	NULL
Lightfoot	NULL
RM	NULL
and	NULL
Brown	NULL
HR	NULL
:	NULL
The	NULL
RXR	NULL
agonist	NULL
LG100268	NULL
causes	NULL
hepatomegaly	NULL
,	NULL
improves	NULL
glycae-mic	NULL
control	NULL
and	NULL
decreases	NULL
cardiovascular	NULL
risk	NULL
and	NULL
cachexia	NULL
in	NULL
diabetic	NULL
mice	NULL
suffering	NULL
from	NULL
pancreatic	NULL
beta-cell	NULL
dysfunction	NULL
.	NULL

Diabetologia	NULL
42	NULL
,	NULL
545	NULL
-	NULL
554	NULL
(	NULL
1999	NULL
)	NULL
Solomin	NULL
L	NULL
,	NULL
Johansson	NULL
CB	NULL
,	NULL
Zetterstrom	NULL
RH	NULL
,	NULL
Bissonnette	NULL
RP	NULL
,	NULL
Heyman	NULL
RA	NULL
,	NULL
Olson	NULL
L	NULL
,	NULL
Lendahl	NULL
U	NULL
,	NULL
Frisen	NULL
J	NULL
and	NULL
Perlmann	NULL
T	NULL
:	NULL
Retinoid-X	NULL
receptor	NULL
signalling	NULL
in	NULL
the	NULL
developing	NULL
spinal	NULL
cord	NULL
.	NULL

Nature	NULL
395	NULL
,	NULL
398	NULL
-	NULL
402	NULL
(	NULL
1998	NULL
)	NULL
Kastner	NULL
P	NULL
,	NULL
Mark	NULL
M	NULL
and	NULL
Chambon	NULL
P	NULL
:	NULL
Nonsteroid	NULL
nuclear	NULL
receptors	NULL
What	NULL
are	NULL
genetic	NULL
studies	NULL
telling	NULL
us	NULL
about	NULL
their	NULL
role	NULL
in	NULL
real	NULL
life	NULL
.	NULL

Cell	NULL
83	NULL
,	NULL
859-869	NULL
(	NULL
1995	NULL
)	NULL
Sucov	NULL
HM	NULL
,	NULL
Dyson	NULL
E	NULL
,	NULL
Gumeringer	NULL
CL	NULL
,	NULL
Price	NULL
J	NULL
,	NULL
Chien	NULL
KR	NULL
and	NULL
20	NULL
21	NULL
22	NULL
23	NULL
24	NULL
25	NULL
26	NULL
27	NULL
28	NULL
29	NULL
30	NULL
31	NULL
32	NULL
33	NULL
Evans	NULL
,	NULL
RM	NULL
:	NULL
RXR	NULL
alpha	NULL
mutant	NULL
mice	NULL
establish	NULL
a	NULL
genetic	NULL
basis	NULL
for	NULL
vitamin	NULL
A	NULL
signaling	NULL
in	NULL
heart	NULL
morphogenesis	NULL
.	NULL

Genes	NULL
Dev	NULL
8	NULL
,	NULL
1007-1018	NULL
(	NULL
1995	NULL
)	NULL
Kastner	NULL
P	NULL
,	NULL
Mark	NULL
M	NULL
,	NULL
Leid	NULL
M	NULL
,	NULL
Gansmuller	NULL
A	NULL
,	NULL
Chin	NULL
W	NULL
,	NULL
Grondona	NULL
JM	NULL
,	NULL
Decimo	NULL
D	NULL
,	NULL
Krezel	NULL
W	NULL
,	NULL
Dierich	NULL
A	NULL
and	NULL
Chambon	NULL
P	NULL
:	NULL
Abnormal	NULL
spermatogenesis	NULL
in	NULL
RXR	NULL
beta	NULL
mutant	NULL
mice	NULL
.	NULL

Genes	NULL
Dev	NULL
10	NULL
,	NULL
80	NULL
82	NULL
(	NULL
1996	NULL
)	NULL
Yoshimura	NULL
H	NULL
,	NULL
Nagai	NULL
M	NULL
,	NULL
Hibi	NULL
S	NULL
,	NULL
Kikuchi	NULL
K	NULL
,	NULL
Abe	NULL
S	NULL
,	NULL
Hida	NULL
T	NULL
,	NULL
Higashi	NULL
S	NULL
,	NULL
Hishinuma	NULL
I	NULL
and	NULL
Yamanaka	NULL
T	NULL
:	NULL
A	NULL
novel	NULL
type	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
antagonist	NULL
synthesis	NULL
and	NULL
structure-activity	NULL
relationships	NULL
of	NULL
heterocyclic	NULL
ring-containing	NULL
benzoic	NULL
acid	NULL
derivatives	NULL
.	NULL

J	NULL
Med	NULL
Chem	NULL
38	NULL
,	NULL
3163	NULL
-	NULL
3173	NULL
(	NULL
1995	NULL
)	NULL
Hibi	NULL
S	NULL
,	NULL
Kikuchi	NULL
K	NULL
,	NULL
Yoshimura	NULL
H	NULL
,	NULL
Nagai	NULL
M	NULL
,	NULL
Tai	NULL
K	NULL
and	NULL
Hida	NULL
T	NULL
:	NULL
Syntheses	NULL
and	NULL
structure-activity	NULL
relationships	NULL
of	NULL
novel	NULL
retinoid	NULL
X	NULL
receptor	NULL
agonists	NULL
.	NULL

J	NULL
Med	NULL
Chem	NULL
41	NULL
,	NULL
3245	NULL
-	NULL
3252	NULL
(	NULL
1998	NULL
)	NULL
Goto	NULL
M	NULL
,	NULL
Yamada	NULL
K	NULL
,	NULL
Katayama	NULL
K	NULL
and	NULL
Tanaka	NULL
I	NULL
:	NULL
Inhibitory	NULL
effect	NULL
of	NULL
E3330	NULL
,	NULL
a	NULL
novel	NULL
quinone	NULL
derivative	NULL
able	NULL
to	NULL
suppress	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
generation	NULL
,	NULL
on	NULL
activation	NULL
of	NULL
nuclear	NULL
factor-xB	NULL
.	NULL

Mol	NULL
Pharmacol	NULL
49	NULL
,	NULL
860	NULL
-	NULL
873	NULL
(	NULL
1996	NULL
)	NULL
Apfel	NULL
C	NULL
,	NULL
Bauer	NULL
F	NULL
,	NULL
Crettaz	NULL
M	NULL
,	NULL
Forni	NULL
L	NULL
,	NULL
Kamber	NULL
M	NULL
,	NULL
Kaufmann	NULL
F	NULL
,	NULL
LeMotte	NULL
P	NULL
,	NULL
Pirson	NULL
W	NULL
and	NULL
Klaus	NULL
M	NULL
:	NULL
A	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
antagonist	NULL
selectively	NULL
counteracts	NULL
retinoic	NULL
acid	NULL
effects	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89	NULL
,	NULL
7129-7133	NULL
(	NULL
1992	NULL
)	NULL
Lala	NULL
DS	NULL
,	NULL
Mukherjee	NULL
R	NULL
,	NULL
Schulman	NULL
IG	NULL
,	NULL
Canon	NULL
Koch	NULL
SS	NULL
,	NULL
Dardashti	NULL
LJ	NULL
,	NULL
Nadzan	NULL
AM	NULL
,	NULL
Croston	NULL
GE	NULL
,	NULL
Evans	NULL
RM	NULL
and	NULL
Heyman	NULL
RA	NULL
:	NULL
Activation	NULL
of	NULL
specific	NULL
RXR	NULL
heterodimers	NULL
by	NULL
an	NULL
antagonist	NULL
of	NULL
RXR	NULL
homodimers	NULL
.	NULL

Nature	NULL
383	NULL
,	NULL
450	NULL
-	NULL
453	NULL
(	NULL
1996	NULL
)	NULL
Ueno	NULL
H	NULL
,	NULL
Kizaki	NULL
M	NULL
,	NULL
Matsushita	NULL
H	NULL
,	NULL
Muto	NULL
A	NULL
,	NULL
Yamato	NULL
K	NULL
,	NULL
Nishihara	NULL
T	NULL
,	NULL
Hida	NULL
T	NULL
,	NULL
Yoshimura	NULL
H	NULL
,	NULL
Koeffler	NULL
HP	NULL
and	NULL
Ikeda	NULL
Y	NULL
:	NULL
A	NULL
novel	NULL
retinoic	NULL
acid	NULL
receptor	NULL
(	NULL
RAR	NULL
)	NULL
-selective	NULL
antagonist	NULL
inhibits	NULL
differentiation	NULL
and	NULL
apoptosis	NULL
of	NULL
HL-60	NULL
cells	NULL
:	NULL
implications	NULL
of	NULL
RARa-mediated	NULL
signals	NULL
in	NULL
myeloid	NULL
leukemic	NULL
cells	NULL
.	NULL

Leukemia	NULL
Res	NULL
22	NULL
,	NULL
517-525	NULL
(	NULL
1998	NULL
)	NULL
Nagy	NULL
L	NULL
,	NULL
Thomazy	NULL
VA	NULL
,	NULL
Shipley	NULL
GL	NULL
,	NULL
Fesus	NULL
WK	NULL
,	NULL
Lamph	NULL
W	NULL
,	NULL
Heyman	NULL
RA	NULL
,	NULL
Chandraratna	NULL
RA	NULL
and	NULL
Davies	NULL
PA	NULL
:	NULL
Activation	NULL
of	NULL
retinoid	NULL
X	NULL
receptors	NULL
induces	NULL
apoptosis	NULL
in	NULL
HL-60	NULL
cell	NULL
lines	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
15	NULL
,	NULL
3540	NULL
-	NULL
3551	NULL
(	NULL
1995	NULL
)	NULL
Nervi	NULL
C	NULL
,	NULL
Grippo	NULL
JF	NULL
,	NULL
Sherman	NULL
MI	NULL
,	NULL
George	NULL
MD	NULL
and	NULL
Jetten	NULL
AM	NULL
:	NULL
Identification	NULL
and	NULL
characterization	NULL
of	NULL
nuclear	NULL
retinoic	NULL
acid-binding	NULL
activity	NULL
in	NULL
human	NULL
myeloblastic	NULL
leukemia	NULL
HL-60	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
86	NULL
,	NULL
5854	NULL
-	NULL
5858	NULL
(	NULL
1989	NULL
)	NULL
Breitman	NULL
TR	NULL
,	NULL
Selonick	NULL
SE	NULL
and	NULL
Collins	NULL
SJ	NULL
:	NULL
Induction	NULL
of	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL-60	NULL
)	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
77	NULL
,	NULL
2936-2940	NULL
(	NULL
1980	NULL
)	NULL
Park	NULL
JR	NULL
,	NULL
Robertson	NULL
K	NULL
,	NULL
Hickstein	NULL
DD	NULL
,	NULL
Tsai	NULL
S	NULL
,	NULL
Hockenbery	NULL
DM	NULL
and	NULL
Collins	NULL
J	NULL
:	NULL
Dysregulated	NULL
bel-2	NULL
expression	NULL
inhibits	NULL
apoptosis	NULL
but	NULL
not	NULL
differentiation	NULL
of	NULL
retinoic	NULL
acid-induced	NULL
HL-60	NULL
granulo-cytes	NULL
.	NULL

Blood	NULL
84	NULL
,	NULL
440	NULL
-	NULL
445	NULL
(	NULL
1994	NULL
)	NULL
Kizaki	NULL
M	NULL
,	NULL
Ikeda	NULL
Y	NULL
,	NULL
Tanosaki	NULL
R	NULL
,	NULL
Nakajima	NULL
H	NULL
,	NULL
Morikawa	NULL
M	NULL
,	NULL
Sakashita	NULL
A	NULL
and	NULL
Koeffler	NULL
H	NULL
:	NULL
Effects	NULL
of	NULL
novel	NULL
retinoic	NULL
acid	NULL
compound	NULL
,	NULL
9-cis-retinoic	NULL
acid	NULL
,	NULL
on	NULL
proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor-alpha	NULL
and	NULL
retinoid	NULL
X	NULL
receptor-alpha	NULL
RNA	NULL
by	NULL
HL-60	NULL
cells	NULL
.	NULL

Blood	NULL
82	NULL
,	NULL
3592-3599	NULL
(	NULL
1993	NULL
)	NULL
Sucov	NULL
HM	NULL
,	NULL
Murakami	NULL
KK	NULL
and	NULL
Evans	NULL
RM	NULL
:	NULL
Characterization	NULL
of	NULL
an	NULL
autoregulated	NULL
response	NULL
element	NULL
in	NULL
the	NULL
mouse	NULL
retinoic	NULL
acid	NULL
receptor	NULL
type	NULL
beta	NULL
gene	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
87	NULL
,	NULL
5392	NULL
5396	NULL
(	NULL
1990	NULL
)	NULL
de	NULL
The	NULL
H	NULL
,	NULL
Vivanco-Ruiz	NULL
dMM	NULL
,	NULL
Tiolais	NULL
P	NULL
,	NULL
Stumenberg	NULL
H	NULL
and	NULL
34	NULL
35	NULL
RXR	NULL
Pathway	NULL
in	NULL
Cellular	NULL
Function	NULL
69	NULL
Dejean	NULL
A	NULL
:	NULL
Identification	NULL
of	NULL
retinoic	NULL
acid	NULL
responsive	NULL
element	NULL
in	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
/3	NULL
gene	NULL
.	NULL

Nature	NULL
343	NULL
,	NULL
177	NULL
-	NULL
180	NULL
(	NULL
1990	NULL
)	NULL
Redfern	NULL
PFC	NULL
,	NULL
Lovat	NULL
PE	NULL
,	NULL
Malcolm	NULL
AJ	NULL
and	NULL
Pearson	NULL
ADJ	NULL
:	NULL
Differential	NULL
effects	NULL
of	NULL
9-cis	NULL
and	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
retinoic	NULL
acid	NULL
and	NULL
cellular	NULL
retinoic	NULL
acid-binding	NULL
protein	NULL
II	NULL
in	NULL
human	NULL
neuroblastoma	NULL
cells	NULL
.	NULL

Biochem	NULL
J	NULL
304	NULL
,	NULL
147	NULL
154	NULL
(	NULL
1994	NULL
)	NULL
Fahlman	NULL
C	NULL
,	NULL
Jakobsen	NULL
SE	NULL
,	NULL
Smeland	NULL
EB	NULL
,	NULL
Lomo	NULL
J	NULL
,	NULL
Naess	NULL
CE	NULL
,	NULL
Funderud	NULL
S	NULL
and	NULL
Blomhoff	NULL
HK	NULL
:	NULL
4//-trans-	NULL
and	NULL
9-cis-retinoic	NULL
acid	NULL
inhibit	NULL
growth	NULL
of	NULL
normal	NULL
human	NULL
and	NULL
murine	NULL
B	NULL
cell	NULL
precursors	NULL
.	NULL

36	NULL
37	NULL
38	NULL
J	NULL
Immunol	NULL
155	NULL
,	NULL
58	NULL
-	NULL
65	NULL
(	NULL
1995	NULL
)	NULL
Mangelsdorf	NULL
DJ	NULL
and	NULL
Evans	NULL
RM	NULL
:	NULL
The	NULL
RXR	NULL
heterodimers	NULL
and	NULL
orphan	NULL
receptors	NULL
.	NULL

Cell	NULL
83	NULL
,	NULL
841	NULL
-	NULL
850	NULL
(	NULL
1995	NULL
)	NULL
Kersten	NULL
S	NULL
,	NULL
Dong	NULL
D	NULL
,	NULL
Lee	NULL
Wy	NULL
,	NULL
Reczek	NULL
PR	NULL
and	NULL
Noy	NULL
N	NULL
:	NULL
Auto-silencing	NULL
by	NULL
the	NULL
retinoid	NULL
Xreceptor	NULL
.	NULL

J	NULL
Mol	NULL
Biol	NULL
284	NULL
,	NULL
21-32	NULL
(	NULL
1998	NULL
)	NULL
Dong	NULL
D	NULL
and	NULL
Noy	NULL
N	NULL
:	NULL
Heterodimer	NULL
formation	NULL
by	NULL
retinoid	NULL
X	NULL
receptor	NULL
:	NULL
regulation	NULL
by	NULL
ligands	NULL
and	NULL
by	NULL
the	NULL
receptor	NULL
's	NULL
self-asso-ciation	NULL
properties	NULL
.	NULL

Biochemistry	NULL
37	NULL
,	NULL
10691-10700	NULL
(	NULL
1998	NULL
)	NULL

